

Form 5500 Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Annual Return/Report of Employee Benefit Plan This form is required to be filed for employee benefit plans under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and sections 6057(b) and 6058(a) of the Internal Revenue Code (the Code). ▶ Complete all entries in accordance with the instructions to the Form 5500.	OMB Nos. 1210-0110 1210-0089 2021 This Form is Open to Public Inspection
---	---	---

Part I	Annual Report Identification Information
For calendar plan year 2021 or fiscal plan year beginning <u>01/01/2021</u> and ending <u>12/31/2021</u>	
A This return/report is for:	☐ a multiemployer plan ☐ a multiple-employer plan (Filers checking this box must attach a list of participating employer information in accordance with the form instructions.) ☒ a single-employer plan ☐ a DFE (specify) _____
B This return/report is:	☐ the first return/report ☐ the final return/report ☐ an amended return/report ☐ a short plan year return/report (less than 12 months)
C If the plan is a collectively-bargained plan, check here.	☐
D Check box if filing under:	☒ Form 5558 ☐ automatic extension ☐ the DFVC program ☐ special extension (enter description)
E If this is a retroactively adopted plan permitted by SECURE Act section 201, check here.	☐

Part II	Basic Plan Information—enter all requested information										
1a Name of plan <u>TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN</u>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%;">1b Three-digit plan number (PN) ▶</td> <td style="width: 20%; text-align: center;"><u>004</u></td> </tr> <tr> <td colspan="2">1c Effective date of plan <u>01/01/1967</u></td> </tr> <tr> <td colspan="2">2b Employer Identification Number (EIN) <u>22-1734359</u></td> </tr> <tr> <td colspan="2">2c Plan Sponsor's telephone number <u>215-591-3000</u></td> </tr> <tr> <td colspan="2">2d Business code (see instructions) <u>325410</u></td> </tr> </table>	1b Three-digit plan number (PN) ▶	<u>004</u>	1c Effective date of plan <u>01/01/1967</u>		2b Employer Identification Number (EIN) <u>22-1734359</u>		2c Plan Sponsor's telephone number <u>215-591-3000</u>		2d Business code (see instructions) <u>325410</u>	
1b Three-digit plan number (PN) ▶	<u>004</u>										
1c Effective date of plan <u>01/01/1967</u>											
2b Employer Identification Number (EIN) <u>22-1734359</u>											
2c Plan Sponsor's telephone number <u>215-591-3000</u>											
2d Business code (see instructions) <u>325410</u>											
2a Plan sponsor's name (employer, if for a single-employer plan) Mailing address (include room, apt., suite no. and street, or P.O. Box) City or town, state or province, country, and ZIP or foreign postal code (if foreign, see instructions) <u>TEVA PHARMACEUTICALS USA, INC.</u> <u>400 INTERPACE PKWY</u> <u>PARSIPPANY, NJ 07054</u>											

Caution: A penalty for the late or incomplete filing of this return/report will be assessed unless reasonable cause is established.

Under penalties of perjury and other penalties set forth in the instructions, I declare that I have examined this return/report, including accompanying schedules, statements and attachments, as well as the electronic version of this return/report, and to the best of my knowledge and belief, it is true, correct, and complete.

SIGN HERE	Filed with authorized/valid electronic signature.	09/28/2022	EDUARDO NASI CHEIDE DA GRACA
	Signature of plan administrator	Date	Enter name of individual signing as plan administrator
SIGN HERE			
	Signature of employer/plan sponsor	Date	Enter name of individual signing as employer or plan sponsor
SIGN HERE			
	Signature of DFE	Date	Enter name of individual signing as DFE

For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

Form 5500 (2021)
v. 210624

3a Plan administrator's name and address ☒ Same as Plan Sponsor		3b Administrator's EIN	
		3c Administrator's telephone number	
4 If the name and/or EIN of the plan sponsor or the plan name has changed since the last return/report filed for this plan, enter the plan sponsor's name, EIN, the plan name and the plan number from the last return/report: a Sponsor's name c Plan Name		4b EIN 4d PN	
5 Total number of participants at the beginning of the plan year		5	11294
6 Number of participants as of the end of the plan year unless otherwise stated (welfare plans complete only lines 6a(1) , 6a(2) , 6b , 6c , and 6d).			
a(1) Total number of active participants at the beginning of the plan year.....		6a(1)	6009
a(2) Total number of active participants at the end of the plan year		6a(2)	5596
b Retired or separated participants receiving benefits.....		6b	126
c Other retired or separated participants entitled to future benefits		6c	5110
d Subtotal. Add lines 6a(2) , 6b , and 6c		6d	10832
e Deceased participants whose beneficiaries are receiving or are entitled to receive benefits.		6e	21
f Total. Add lines 6d and 6e		6f	10853
g Number of participants with account balances as of the end of the plan year (only defined contribution plans complete this item)		6g	10417
h Number of participants who terminated employment during the plan year with accrued benefits that were less than 100% vested		6h	399
7 Enter the total number of employers obligated to contribute to the plan (only multiemployer plans complete this item).....		7	
8a If the plan provides pension benefits, enter the applicable pension feature codes from the List of Plan Characteristics Codes in the instructions: 2G 2J 2K 2S 2T 2E 3H 2F			
b If the plan provides welfare benefits, enter the applicable welfare feature codes from the List of Plan Characteristics Codes in the instructions:			
9a Plan funding arrangement (check all that apply) (1) ☐ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor		9b Plan benefit arrangement (check all that apply) (1) ☐ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor	
10 Check all applicable boxes in 10a and 10b to indicate which schedules are attached, and, where indicated, enter the number attached. (See instructions)			
a Pension Schedules (1) ☒ R (Retirement Plan Information) (2) ☐ MB (Multiemployer Defined Benefit Plan and Certain Money Purchase Plan Actuarial Information) - signed by the plan actuary (3) ☐ SB (Single-Employer Defined Benefit Plan Actuarial Information) - signed by the plan actuary		b General Schedules (1) ☒ H (Financial Information) (2) ☐ I (Financial Information – Small Plan) (3) ☐ <u>0</u> A (Insurance Information) (4) ☒ C (Service Provider Information) (5) ☒ D (DFE/Participating Plan Information) (6) ☐ G (Financial Transaction Schedules)	

Part III Form M-1 Compliance Information (to be completed by welfare benefit plans)

11a If the plan provides welfare benefits, was the plan subject to the Form M-1 filing requirements during the plan year? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

If "Yes" is checked, complete lines 11b and 11c.

11b Is the plan currently in compliance with the Form M-1 filing requirements? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

11c Enter the Receipt Confirmation Code for the 2021 Form M-1 annual report. If the plan was not required to file the 2021 Form M-1 annual report, enter the Receipt Confirmation Code for the most recent Form M-1 that was required to be filed under the Form M-1 filing requirements. (Failure to enter a valid Receipt Confirmation Code will subject the Form 5500 filing to rejection as incomplete.)

Receipt Confirmation Code _____

SCHEDULE C (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Service Provider Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110
		2021
		This Form is Open to Public Inspection.

For calendar plan year 2021 or fiscal plan year beginning 01/01/2021 and ending 12/31/2021		
A Name of plan TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN	B Three-digit plan number (PN) ▶	004
C Plan sponsor's name as shown on line 2a of Form 5500 TEVA PHARMACEUTICALS USA, INC.	D Employer Identification Number (EIN) 22-1734359	

Part I	Service Provider Information (see instructions)
---------------	--

You must complete this Part, in accordance with the instructions, to report the information required for **each person** who received, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of monetary value) in connection with services rendered to the plan or the person's position with the plan during the plan year. If a person received **only** eligible indirect compensation for which the plan received the required disclosures, you are required to answer line 1 but are not required to include that person when completing the remainder of this Part.

1 Information on Persons Receiving Only Eligible Indirect Compensation

- a** Check "Yes" or "No" to indicate whether you are excluding a person from the remainder of this Part because they received only eligible indirect compensation for which the plan received the required disclosures (see instructions for definitions and conditions)..... ☒ Yes ☐ No
- b** If you answered line 1a "Yes," enter the name and EIN or address of each person providing the required disclosures for the service providers who received only eligible indirect compensation. Complete as many entries as needed (see instructions).

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL
04-2647786

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

2. Information on Other Service Providers Receiving Direct or Indirect Compensation. Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

FIDELITY INVESTMENTS INSTITUTIONAL

04-2647786

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
37 60 64 65	RECORDKEEPER	574276	Yes ☒ No ☐	Yes ☒ No ☐	0	Yes ☒ No ☐

(a) Enter name and EIN or address (see instructions)

AON INVESTMENTS USA INC.

36-3109431

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
27	CONSULTANT	70141	Yes ☐ No ☒	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

2. Information on Other Service Providers Receiving Direct or Indirect Compensation. Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

Part I Service Provider Information (continued)

3. If you reported on line 2 receipt of indirect compensation, other than eligible indirect compensation, by a service provider, and the service provider is a fiduciary or provides contract administrator, consulting, custodial, investment advisory, investment management, broker, or recordkeeping services, answer the following questions for (a) each source from whom the service provider received \$1,000 or more in indirect compensation and (b) each source for whom the service provider gave you a formula used to determine the indirect compensation instead of an amount or estimated amount of the indirect compensation. Complete as many entries as needed to report the required information for each source.

(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL	60	0
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
C&S INST REALTY SHS - DST ASSET MA 430 W 7TH STREET STE 219432 KANSAS CITY, MO 64105	0.10%	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL	60	0
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
TRP UST MONEY FUND - T. ROWE PRICE 52-2269240	0.15%	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	

Part II Service Providers Who Fail or Refuse to Provide Information

4 Provide, to the extent possible, the following information for each service provider who failed or refused to provide the information necessary to complete this Schedule.

(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide

Part III Termination Information on Accountants and Enrolled Actuaries (see instructions)
(complete as many entries as needed)

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

SCHEDULE D (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration	DFE/Participating Plan Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ► File as an attachment to Form 5500.	OMB No. 1210-0110 2021 This Form is Open to Public Inspection.
---	--	--

For calendar plan year 2021 or fiscal plan year beginning 01/01/2021 and ending 12/31/2021

A Name of plan <u>TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN</u>	B Three-digit plan number (PN) <u>004</u>
C Plan or DFE sponsor's name as shown on line 2a of Form 5500 <u>TEVA PHARMACEUTICALS USA, INC.</u>	D Employer Identification Number (EIN) <u>22-1734359</u>

Part I	Information on interests in MTIAs, CCTs, PSAs, and 103-12 IEs (to be completed by plans and DFEs) (Complete as many entries as needed to report all interests in DFEs)
---------------	--

a Name of MTIA, CCT, PSA, or 103-12 IE: <u>TRP STABLE VALUE N</u>		
b Name of sponsor of entity listed in (a): <u>T. ROWE PRICE TRUST COMPANY</u>		
c EIN-PN <u>52-1309931-001</u>	d Entity code <u>C</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>0</u>
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>FID LOW PR STK POOL</u>		
b Name of sponsor of entity listed in (a): <u>FIDELITY MANAGEMENT TRUST COMPANY</u>		
c EIN-PN <u>04-3022712-132</u>	d Entity code <u>C</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>0</u>
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>FID CONTRAFUND POOL</u>		
b Name of sponsor of entity listed in (a): <u>FIDELITY MANAGEMENT TRUST COMPANY</u>		
c EIN-PN <u>04-3022712-133</u>	d Entity code <u>C</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>0</u>
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>SS TRGT RET 2020 IV</u>		
b Name of sponsor of entity listed in (a): <u>STATE STREET GLOBAL ADVISORS TRUST</u>		
c EIN-PN <u>32-6528132-021</u>	d Entity code <u>C</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>69125227</u>
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>SS TRGT RET 2055 IV</u>		
b Name of sponsor of entity listed in (a): <u>STATE STREET GLOBAL ADVISORS TRUST</u>		
c EIN-PN <u>32-6528132-028</u>	d Entity code <u>C</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>26504251</u>
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>SS GACEQ EXUS IDX II</u>		
b Name of sponsor of entity listed in (a): <u>STATE STREET BANK & TRUST COMPANY</u>		
c EIN-PN <u>90-0337987-444</u>	d Entity code <u>C</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>42651872</u>
a Name of MTIA, CCT, PSA, or 103-12 IE: <u>SS TRGT RET 2065 IV</u>		
b Name of sponsor of entity listed in (a): <u>STATE STREET GLOBAL ADVISORS TRUST</u>		
c EIN-PN <u>32-6528132-045</u>	d Entity code <u>C</u>	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) <u>1212567</u>

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET 2035 IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-024	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 222285108
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET 2040 IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-025	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 199044196
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET 2030 IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-023	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 220138259
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET 2060 IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-029	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 7719265
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET 2025 IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-022	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 136817873
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: SS S&P 500 INDEX II

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 04-0025081-078	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 282096740
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET 2045 IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-026	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 141267757
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET 2050 IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-027	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 59421758
--------------------------------	------------------------	--

a Name of MTIA, CCT, PSA, or 103-12 IE: SS TRGT RET INC IV

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-030	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 25072346
--------------------------------	------------------------	--

a Name of MTIA, CCT, PSA, or 103-12 IE: SS US BOND INDX XIV

b Name of sponsor of entity listed in (a): STATE STREET BANK & TRUST COMPANY

c EIN-PN 90-0337987-477	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 50438497
--------------------------------	------------------------	--

a Name of MTIA, CCT, PSA, or 103-12 IE: SS RSL SMMDCP IDX II

b Name of sponsor of entity listed in (a): STATE STREET GLOBAL ADVISORS TRUST

c EIN-PN 32-6528132-019	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 131230640
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: TRP LRG CAP GR TR D

b Name of sponsor of entity listed in (a): T. ROWE PRICE TRUST COMPANY

c EIN-PN 32-6528532-001	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 288755698
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE: TRP STABLE VALUE Q

b Name of sponsor of entity listed in (a): T. ROWE PRICE TRUST COMPANY

c EIN-PN 52-1309931-003	d Entity code C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions) 145181108
--------------------------------	------------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:

b Name of sponsor of entity listed in (a):

c EIN-PN	d Entity code	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)
-----------------	----------------------	---

Part II Information on Participating Plans (to be completed by DFEs)

(Complete as many entries as needed to report all participating plans)

a Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN

SCHEDULE H (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Financial Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 6058(a) of the Internal Revenue Code (the Code). ► File as an attachment to Form 5500.	OMB No. 1210-0110 2021 This Form is Open to Public Inspection
--	--	--

For calendar plan year 2021 or fiscal plan year beginning <u>01/01/2021</u> and ending <u>12/31/2021</u>		
A Name of plan <u>TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN</u>	B Three-digit plan number (PN) ►	<u>004</u>
C Plan sponsor's name as shown on line 2a of Form 5500 <u>TEVA PHARMACEUTICALS USA, INC.</u>	D Employer Identification Number (EIN) <u>22-1734359</u>	

Part I	Asset and Liability Statement
---------------	--------------------------------------

1 Current value of plan assets and liabilities at the beginning and end of the plan year. Combine the value of plan assets held in more than one trust. Report the value of the plan's interest in a commingled fund containing the assets of more than one plan on a line-by-line basis unless the value is reportable on lines 1c(9) through 1c(14). Do not enter the value of that portion of an insurance contract which guarantees, during this plan year, to pay a specific dollar benefit at a future date. **Round off amounts to the nearest dollar.** MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 1b(1), 1b(2), 1c(8), 1g, 1h, and 1i. CCTs, PSAs, and 103-12 IEs also do not complete lines 1d and 1e. See instructions.

Assets		(a) Beginning of Year	(b) End of Year
a Total noninterest-bearing cash.....	1a	0	0
b Receivables (less allowance for doubtful accounts):			
(1) Employer contributions	1b(1)	29710005	22825731
(2) Participant contributions.....	1b(2)	1436115	1331477
(3) Other	1b(3)	0	0
c General investments:			
(1) Interest-bearing cash (include money market accounts & certificates of deposit)	1c(1)	1814595	4948470
(2) U.S. Government securities	1c(2)	0	0
(3) Corporate debt instruments (other than employer securities):			
(A) Preferred	1c(3)(A)	0	0
(B) All other	1c(3)(B)	0	0
(4) Corporate stocks (other than employer securities):			
(A) Preferred	1c(4)(A)	0	0
(B) Common	1c(4)(B)	0	0
(5) Partnership/joint venture interests	1c(5)	0	0
(6) Real estate (other than employer real property)	1c(6)	0	0
(7) Loans (other than to participants)	1c(7)	0	0
(8) Participant loans	1c(8)	21604568	19528596
(9) Value of interest in common/collective trusts	1c(9)	1869938589	2048963162
(10) Value of interest in pooled separate accounts	1c(10)	0	0
(11) Value of interest in master trust investment accounts	1c(11)	0	0
(12) Value of interest in 103-12 investment entities	1c(12)	0	0
(13) Value of interest in registered investment companies (e.g., mutual funds)	1c(13)	247421228	276205061
(14) Value of funds held in insurance company general account (unallocated contracts).....	1c(14)	0	0
(15) Other.....	1c(15)	0	0

1d Employer-related investments:		(a) Beginning of Year	(b) End of Year
(1) Employer securities.....	1d(1)	0	0
(2) Employer real property.....	1d(2)	0	0
e Buildings and other property used in plan operation	1e	0	0
f Total assets (add all amounts in lines 1a through 1e)	1f	2171925100	2373802497

Liabilities

g Benefit claims payable	1g	0	0
h Operating payables	1h	0	0
i Acquisition indebtedness.....	1i	0	0
j Other liabilities.....	1j	20507	22055
k Total liabilities (add all amounts in lines 1g through 1j)	1k	20507	22055

Net Assets

l Net assets (subtract line 1k from line 1f)	1l	2171904593	2373780442
---	-----------	------------	------------

Part II Income and Expense Statement

2 Plan income, expenses, and changes in net assets for the year. Include all income and expenses of the plan, including any trust(s) or separately maintained fund(s) and any payments/receipts to/from insurance carriers. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 2a, 2b(1)(E), 2e, 2f, and 2g.

Income

		(a) Amount	(b) Total
a Contributions:			
(1) Received or receivable in cash from: (A) Employers	2a(1)(A)	59070682	
(B) Participants	2a(1)(B)	60564322	
(C) Others (including rollovers).....	2a(1)(C)	14599386	
(2) Noncash contributions.....	2a(2)	0	134234390
(3) Total contributions. Add lines 2a(1)(A) , (B) , (C) , and line 2a(2)	2a(3)		
b Earnings on investments:			
(1) Interest:			
(A) Interest-bearing cash (including money market accounts and certificates of deposit).....	2b(1)(A)	2665176	
(B) U.S. Government securities	2b(1)(B)	0	
(C) Corporate debt instruments	2b(1)(C)	0	
(D) Loans (other than to participants)	2b(1)(D)	0	
(E) Participant loans.....	2b(1)(E)	1097508	
(F) Other	2b(1)(F)	0	
(G) Total interest. Add lines 2b(1)(A) through (F)	2b(1)(G)		3762684
(2) Dividends: (A) Preferred stock.....	2b(2)(A)	0	31057686
(B) Common stock	2b(2)(B)	0	
(C) Registered investment company shares (e.g. mutual funds).....	2b(2)(C)	31057686	
(D) Total dividends. Add lines 2b(2)(A) , (B) , and (C)	2b(2)(D)		31057686
(3) Rents	2b(3)		0
(4) Net gain (loss) on sale of assets: (A) Aggregate proceeds	2b(4)(A)	0	
(B) Aggregate carrying amount (see instructions).....	2b(4)(B)	0	
(C) Subtract line 2b(4)(B) from line 2b(4)(A) and enter result	2b(4)(C)		0
(5) Unrealized appreciation (depreciation) of assets: (A) Real estate	2b(5)(A)	0	
(B) Other	2b(5)(B)	0	
(C) Total unrealized appreciation of assets. Add lines 2b(5)(A) and (B)	2b(5)(C)		0

		(a) Amount	(b) Total
(6) Net investment gain (loss) from common/collective trusts.....	2b(6)		256303929
(7) Net investment gain (loss) from pooled separate accounts.....	2b(7)		0
(8) Net investment gain (loss) from master trust investment accounts.....	2b(8)		0
(9) Net investment gain (loss) from 103-12 investment entities.....	2b(9)		0
(10) Net investment gain (loss) from registered investment companies (e.g., mutual funds).....	2b(10)		34764902
c Other income.....	2c		1105200
d Total income. Add all income amounts in column (b) and enter total.....	2d		461228791
Expenses			
e Benefit payment and payments to provide benefits:			
(1) Directly to participants or beneficiaries, including direct rollovers.....	2e(1)	258584222	
(2) To insurance carriers for the provision of benefits.....	2e(2)	0	
(3) Other.....	2e(3)	0	
(4) Total benefit payments. Add lines 2e(1) through (3).....	2e(4)		258584222
f Corrective distributions (see instructions).....	2f		47147
g Certain deemed distributions of participant loans (see instructions).....	2g		77156
h Interest expense.....	2h		0
i Administrative expenses: (1) Professional fees.....	2i(1)	0	
(2) Contract administrator fees.....	2i(2)	0	
(3) Investment advisory and management fees.....	2i(3)	0	
(4) Other.....	2i(4)	644417	
(5) Total administrative expenses. Add lines 2i(1) through (4).....	2i(5)		644417
j Total expenses. Add all expense amounts in column (b) and enter total.....	2j		259352942
Net Income and Reconciliation			
k Net income (loss). Subtract line 2j from line 2d.....	2k		201875849
l Transfers of assets:			
(1) To this plan.....	2l(1)		0
(2) From this plan.....	2l(2)		0

Part III Accountant's Opinion

3 Complete lines 3a through 3c if the opinion of an independent qualified public accountant is attached to this Form 5500. Complete line 3d if an opinion is not attached.

a The attached opinion of an independent qualified public accountant for this plan is (see instructions):

(1) ☒ Unmodified (2) ☐ Qualified (3) ☐ Disclaimer (4) ☐ Adverse

b Check the appropriate box(es) to indicate whether the IQPA performed an ERISA section 103(a)(3)(C) audit. Check both boxes (1) and (2) if the audit was performed pursuant to both 29 CFR 2520.103-8 and 29 CFR 2520.103-12(d). Check box (3) if pursuant to neither.

(1) ☒ DOL Regulation 2520.103-8 (2) ☐ DOL Regulation 2520.103-12(d) (3) ☐ neither DOL Regulation 2520.103-8 nor DOL Regulation 2520.103-12(d).

c Enter the name and EIN of the accountant (or accounting firm) below:

(1) Name: **TORRILLO & ASSOCIATES, LLC**

(2) EIN: **83-0414789**

d The opinion of an independent qualified public accountant is **not attached** because:

(1) ☐ This form is filed for a CCT, PSA, or MTIA. (2) ☐ It will be attached to the next Form 5500 pursuant to 29 CFR 2520.104-50.

Part IV Compliance Questions

4 CCTs and PSAs do not complete Part IV. MTIAs, 103-12 IEs, and GIAs do not complete lines 4a, 4e, 4f, 4g, 4h, 4k, 4m, 4n, or 5. 103-12 IEs also do not complete lines 4j and 4l. MTIAs also do not complete line 4l.

During the plan year:

a Was there a failure to transmit to the plan any participant contributions within the time period described in 29 CFR 2510.3-102? Continue to answer "Yes" for any prior year failures until fully corrected. (See instructions and DOL's Voluntary Fiduciary Correction Program.).....

	Yes	No	Amount
4a	X		4024

	Yes	No	Amount
b Were any loans by the plan or fixed income obligations due the plan in default as of the close of the plan year or classified during the year as uncollectible? Disregard participant loans secured by participant's account balance. (Attach Schedule G (Form 5500) Part I if "Yes" is checked.)			
4b		X	
c Were any leases to which the plan was a party in default or classified during the year as uncollectible? (Attach Schedule G (Form 5500) Part II if "Yes" is checked.)			
4c		X	
d Were there any nonexempt transactions with any party-in-interest? (Do not include transactions reported on line 4a. Attach Schedule G (Form 5500) Part III if "Yes" is checked.)			
4d		X	
e Was this plan covered by a fidelity bond?	X		1000000
f Did the plan have a loss, whether or not reimbursed by the plan's fidelity bond, that was caused by fraud or dishonesty?		X	
4f		X	
g Did the plan hold any assets whose current value was neither readily determinable on an established market nor set by an independent third party appraiser?		X	
4g		X	
h Did the plan receive any noncash contributions whose value was neither readily determinable on an established market nor set by an independent third party appraiser?		X	
4h		X	
i Did the plan have assets held for investment? (Attach schedule(s) of assets if "Yes" is checked, and see instructions for format requirements.)	X		
4i	X		
j Were any plan transactions or series of transactions in excess of 5% of the current value of plan assets? (Attach schedule of transactions if "Yes" is checked and see instructions for format requirements.)		X	
4j		X	
k Were all the plan assets either distributed to participants or beneficiaries, transferred to another plan, or brought under the control of the PBGC?		X	
4k		X	
l Has the plan failed to provide any benefit when due under the plan?		X	
4l		X	
m If this is an individual account plan, was there a blackout period? (See instructions and 29 CFR 2520.101-3.)		X	
4m		X	
n If 4m was answered "Yes," check the "Yes" box if you either provided the required notice or one of the exceptions to providing the notice applied under 29 CFR 2520.101-3.		X	
4n		X	

5a Has a resolution to terminate the plan been adopted during the plan year or any prior plan year? ☐ Yes ☒ No
If "Yes," enter the amount of any plan assets that reverted to the employer this year _____.

5b If, during this plan year, any assets or liabilities were transferred from this plan to another plan(s), identify the plan(s) to which assets or liabilities were transferred. (See instructions.)

5b(1) Name of plan(s)	5b(2) EIN(s)	5b(3) PN(s)

5c Was the plan a defined benefit plan covered under the PBGC insurance program at any time during this plan year? (See ERISA section 4021 and instructions.) ☐ Yes ☐ No ☐ Not determined
If "Yes" is checked, enter the My PAA confirmation number from the PBGC premium filing for this plan year _____.

SCHEDULE R (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Retirement Plan Information This schedule is required to be filed under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and section 6058(a) of the Internal Revenue Code (the Code). ► File as an attachment to Form 5500.	OMB No. 1210-0110 2021 This Form is Open to Public Inspection.
---	--	---

For calendar plan year 2021 or fiscal plan year beginning 01/01/2021 and ending 12/31/2021

A Name of plan TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN	B Three-digit plan number (PN) ► 004
C Plan sponsor's name as shown on line 2a of Form 5500 TEVA PHARMACEUTICALS USA, INC.	D Employer Identification Number (EIN) 22-1734359

Part I	Distributions
--------	---------------

All references to distributions relate only to payments of benefits during the plan year.

1 Total value of distributions paid in property other than in cash or the forms of property specified in the instructions.....	1
2 Enter the EIN(s) of payor(s) who paid benefits on behalf of the plan to participants or beneficiaries during the year (if more than two, enter EINs of the two payors who paid the greatest dollar amounts of benefits): EIN(s): 04-6568107	
Profit-sharing plans, ESOPs, and stock bonus plans, skip line 3.	
3 Number of participants (living or deceased) whose benefits were distributed in a single sum, during the plan year	3

Part II	Funding Information (If the plan is not subject to the minimum funding requirements of section 412 of the Internal Revenue Code or ERISA section 302, skip this Part.)
---------	--

4 Is the plan administrator making an election under Code section 412(d)(2) or ERISA section 302(d)(2)?	☐ Yes ☐ No ☐ N/A
If the plan is a defined benefit plan, go to line 8.	
5 If a waiver of the minimum funding standard for a prior year is being amortized in this plan year, see instructions and enter the date of the ruling letter granting the waiver. Date: Month _____ Day _____ Year _____ If you completed line 5, complete lines 3, 9, and 10 of Schedule MB and do not complete the remainder of this schedule.	
6 a Enter the minimum required contribution for this plan year (include any prior year accumulated funding deficiency not waived)	6a
b Enter the amount contributed by the employer to the plan for this plan year	6b
c Subtract the amount in line 6b from the amount in line 6a. Enter the result (enter a minus sign to the left of a negative amount).....	6c
If you completed line 6c, skip lines 8 and 9.	
7 Will the minimum funding amount reported on line 6c be met by the funding deadline?	☐ Yes ☐ No ☐ N/A
8 If a change in actuarial cost method was made for this plan year pursuant to a revenue procedure or other authority providing automatic approval for the change or a class ruling letter, does the plan sponsor or plan administrator agree with the change?	☐ Yes ☐ No ☐ N/A

Part III	Amendments
----------	------------

9 If this is a defined benefit pension plan, were any amendments adopted during this plan year that increased or decreased the value of benefits? If yes, check the appropriate box. If no, check the "No" box.....	☐ Increase ☐ Decrease ☐ Both ☐ No
--	--

Part IV	ESOPs (see instructions). If this is not a plan described under section 409(a) or 4975(e)(7) of the Internal Revenue Code, skip this Part.
---------	--

10 Were unallocated employer securities or proceeds from the sale of unallocated securities used to repay any exempt loan?	☐ Yes ☐ No
11 a Does the ESOP hold any preferred stock?	☐ Yes ☐ No
b If the ESOP has an outstanding exempt loan with the employer as lender, is such loan part of a "back-to-back" loan? (See instructions for definition of "back-to-back" loan.)	☐ Yes ☐ No
12 Does the ESOP hold any stock that is not readily tradable on an established securities market?	☐ Yes ☐ No

For Paperwork Reduction Act Notice, see the Instructions for Form 5500.

Schedule R (Form 5500) 2021
v. 201209

Part V Additional Information for Multiemployer Defined Benefit Pension Plans

13 Enter the following information for each employer that contributed more than 5% of total contributions to the plan during the plan year (measured in dollars). See instructions. *Complete as many entries as needed to report all applicable employers.*

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

- 14** Enter the number of deferred vested and retired participants (inactive participants), as of the beginning of the plan year, whose contributing employer is no longer making contributions to the plan for:

a The current plan year. Check the box to indicate the counting method used to determine the number of inactive participants: ☐ last contributing employer ☐ alternative ☐ reasonable approximation (see instructions for required attachment).....

14a

b The plan year immediately preceding the current plan year. ☐ Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....

14b

c The second preceding plan year. ☐ Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....

14c

- 15** Enter the ratio of the number of participants under the plan on whose behalf no employer had an obligation to make an employer contribution during the current plan year to:

a The corresponding number for the plan year immediately preceding the current plan year.....

15a

b The corresponding number for the second preceding plan year

15b

- 16** Information with respect to any employers who withdrew from the plan during the preceding plan year:

a Enter the number of employers who withdrew during the preceding plan year

16a

b If line 16a is greater than 0, enter the aggregate amount of withdrawal liability assessed or estimated to be assessed against such withdrawn employers.....

16b

- 17** If assets and liabilities from another plan have been transferred to or merged with this plan during the plan year, check box and see instructions regarding supplemental information to be included as an attachment..... ☐

Part VI Additional Information for Single-Employer and Multiemployer Defined Benefit Pension Plans

- 18** If any liabilities to participants or their beneficiaries under the plan as of the end of the plan year consist (in whole or in part) of liabilities to such participants and beneficiaries under two or more pension plans as of immediately before such plan year, check box and see instructions regarding supplemental information to be included as an attachment..... ☐

- 19** If the total number of participants is 1,000 or more, complete lines (a) through (c)

a Enter the percentage of plan assets held as:

Stock: _____% Investment-Grade Debt: _____% High-Yield Debt: _____% Real Estate: _____% Other: _____%

b Provide the average duration of the combined investment-grade and high-yield debt:

☐ 0-3 years ☐ 3-6 years ☐ 6-9 years ☐ 9-12 years ☐ 12-15 years ☐ 15-18 years ☐ 18-21 years ☐ 21 years or more

c What duration measure was used to calculate line 19(b)?

☐ Effective duration ☐ Macaulay duration ☐ Modified duration ☐ Other (specify): _____

- 20 PBGC missed contribution reporting requirements.** If this is a multiemployer plan or a single-employer plan that is not covered by PBGC, skip line 20.

a Is the amount of unpaid minimum required contributions for all years from Schedule SB (Form 5500) line 40 greater than zero? ☐ Yes ☐ No

b If line 20a is "Yes," has PBGC been notified as required by ERISA sections 4043(c)(5) and/or 303(k)(4)? Check the applicable box:

☐ Yes.

☐ No. Reporting was waived under 29 CFR 4043.25(c)(2) because contributions equal to or exceeding the unpaid minimum required contribution were made by the 30th day after the due date.

☐ No. The 30-day period referenced in 29 CFR 4043.25(c)(2) has not yet ended, and the sponsor intends to make a contribution equal to or exceeding the unpaid minimum required contribution by the 30th day after the due date.

☐ No. Other. Provide explanation _____

TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN

**Financial Statements
As of and for the Years Ended
December 31, 2021 and 2020
And
Supplemental Schedules
As of and For the Year Ended
December 31, 2021**

**Torrillo &
Associates** Certified Public Accountants

Teva Pharmaceuticals Retirement Savings Plan Index

	Page(s)
Independent Auditor's Report	1 - 3
Financial Statements:	
Statements of Net Assets Available for Benefits	4
Statements of Changes in Net Assets Available for Benefits	5
Notes to Financial Statements	6 - 13
Supplemental Schedules:	
Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)	S.1
Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions	S.2
• The supplemental schedules included are presented for purposes of additional analysis and are not a required part of the financial statements but are required by the Employee Retirement Income Security Act of 1974, as amended ("ERISA"). Other schedules required by section 2520.103-10 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable.	

INDEPENDENT AUDITOR'S REPORT

To the Plan Administrator of the Teva Pharmaceuticals Retirement Savings Plan

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements

We have performed an audit of the accompanying financial statements of the Teva Pharmaceuticals Retirement Savings Plan, an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C) ("ERISA Section 103(a)(3)(C) audit"). The financial statements comprise the statement of net assets available for benefits as of December 31, 2021, and the related statement of changes in net assets available for benefits for the year then ended, and the related notes to the financial statements ("2021 Financial Statements").

Plan management, having determined it is permissible in the circumstances, has elected to have the audit of the 2021 Financial Statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the Plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Plan management has obtained a certification from a qualified institution as of and for the year ended December 31, 2021, stating that the certified investment information, as described in Note 3 to the financial statements, is complete and accurate.

Opinion on the 2021 Financial Statements

In our opinion, based on our audit and on the procedures performed as described in the *Auditor's Responsibilities for the Audit of the 2021 Financial Statements* section:

- the amounts and disclosures in the 2021 Financial Statements referred to above, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- the information in the 2021 Financial Statements referred to above related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that Plan management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion on the 2021 Financial Statements

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the 2021 Financial Statements* section of our report. We are required to be independent of the Teva Pharmaceuticals Retirement Savings Plan and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Plan Management for the Financial Statements

Plan management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Plan management's election of the ERISA Section 103(a)(3)(C) audit does not affect Plan management's responsibility for the financial statements.

In preparing the financial statements, Plan management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Teva Pharmaceuticals Retirement Savings Plan's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Plan management is also responsible for maintaining a current Plan instrument, including all Plan amendments; administering the Plan; and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditor's Responsibilities for the Audit of the 2021 Financial Statements

Except as described in the *Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements* section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Teva Pharmaceuticals Retirement Savings Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by Plan management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Teva Pharmaceuticals Retirement Savings Plan's ability to continue as a going concern for a reasonable period of time.

Our audit did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the 2021 Financial Statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matter—2021 Supplemental Schedules Required by ERISA

The supplemental Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year) as of December 31, 2021, and Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions for the year ended December 31, 2021, are presented for purposes of additional analysis and are not a required part of the financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of Plan management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including their form and content, are presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- the form and content of the supplemental schedules, other than the information in the supplemental schedules that agreed to or is derived from the certified investment information, are presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- the information in the supplemental schedules related to assets held by and certified to by a qualified institution agrees to or is derived from, in all material respects, the information prepared and certified by an institution that Plan management determined meets the requirements of ERISA Section 103(a)(3)(C).

Other Matter—Auditor's Report on the 2020 Financial Statements

We were engaged to audit the 2020 financial statements of the Teva Pharmaceuticals Retirement Savings Plan. As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA, the Plan administrator instructed us not to perform and we did not perform any auditing procedures with respect to the information certified by a qualified institution. In our report dated September 29, 2021, we indicated that (a) because of the significance of the information that we did not audit, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion and accordingly, we did not express an opinion on the 2020 financial statements, and (b) the form and content of the information included in the 2020 financial statements other than that derived from the certified information were presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

Touille & Associates, LLC

September 22, 2022

Teva Pharmaceuticals Retirement Savings Plan
Statements of Net Assets Available for Benefits
As of December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Assets:		
Investments, at fair value	\$ 2,330,116,693	\$ 2,119,174,412
Receivables:		
Employee contributions	1,331,477	1,436,115
Employer contributions	22,825,731	29,710,005
Notes receivable from participants	19,528,596	21,604,568
Total receivables	<u>43,685,804</u>	<u>52,750,688</u>
Total assets	2,373,802,497	2,171,925,100
Liabilities:		
Excess contributions payable	<u>22,055</u>	<u>20,507</u>
Total liabilities	<u>22,055</u>	<u>20,507</u>
Net assets available for benefits	<u>\$ 2,373,780,442</u>	<u>\$ 2,171,904,593</u>

The accompanying notes are an integral part of these financial statements.

Teva Pharmaceuticals Retirement Savings Plan
Statements of Changes in Net Assets Available for Benefits
For the Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Additions to net assets attributed to:		
Investment income:		
Net appreciation in fair value of investments	\$ 291,068,831	\$ 297,670,428
Dividends	31,057,686	16,731,689
Interest	2,665,176	617,824
Other income	93,958	38,896
Investment income	<u>324,885,651</u>	<u>315,058,837</u>
Interest income on notes receivable from participants	1,097,508	1,287,491
Contributions:		
Employee contributions	60,564,322	62,608,099
Employer contributions	59,070,682	68,160,559
Rollover contributions	14,599,386	12,545,560
Total contributions	<u>134,234,390</u>	<u>143,314,218</u>
Proceeds from settlement (see Note 8)	<u>1,011,242</u>	<u>-</u>
Total additions	461,228,791	459,660,546
Deductions from net assets attributed to:		
Benefits paid to participants	258,708,525	252,119,837
Administrative expenses	644,417	490,132
Total deductions	<u>259,352,942</u>	<u>252,609,969</u>
Net increase in net assets available for benefits	201,875,849	207,050,577
Net assets available for benefits		
Beginning of year	2,171,904,593	1,964,854,016
End of year	<u>\$ 2,373,780,442</u>	<u>\$ 2,171,904,593</u>

The accompanying notes are an integral part of these financial statements.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

1. Description of Plan

The following description of the Teva Pharmaceuticals Retirement Savings Plan (the “Plan”) provides only general information. Participants should refer to the Summary Plan Description and the Plan document for a more complete description of the Plan’s provisions. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”).

General

The Plan is a defined contribution plan sponsored by Teva Pharmaceuticals USA, Inc. (“Teva” or the “Company”). Employees covered by a collective bargaining agreement, nonresident aliens, leased employees, employees rendering services in Puerto Rico who are receiving income that is taxable under the Puerto Rico Internal Revenue Code of 2011, as amended, and temporary or independent contractors are generally excluded from participating in the Plan. Employees are able to enroll in the Plan beginning the first day of each calendar month after their date of hire. Effective January 1, 2019, the Plan was amended and restated. Fidelity Management Trust Company is the trustee of the Plan.

Contributions

Participants may contribute 1% to 75% of compensation as a tax-deferred contribution or as a Roth contribution, as defined in the Plan. A participant may not elect to make both tax-deferred contributions and Roth contributions with respect to the same payroll period. In the event a participant fails to designate whether his or her elective contributions are to be characterized as tax-deferred or Roth contributions, such elective contributions will be characterized as tax-deferred. Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans.

The Plan provides for employer matching contributions which equal 100% of the first 6% of employee contributions.

As detailed in the Plan document, new employees are subject to automatic enrollment and will be deemed to have elected to make tax-deferred contributions to the Plan at a rate equal to 4% of their eligible compensation. Such tax-deferred contributions commence with respect to the first payday that occurs on the date with or following the 45th day following the date the employee is eligible to participate in the Plan. The participant will be provided a notice describing the terms and conditions of automatic enrollment and has until the end of the 45-day period to elect not to make automatic tax-deferred contributions, to modify the amount of such tax-deferred contributions, or to make Roth contributions. Such participant may withdraw their contributions, plus any income and minus any losses by notifying the Teva Pharmaceuticals USA, Inc. Compensation and Employee Benefits Committee (the “Committee”) during the 90-day period following the first contribution. In the absence of investment direction by the participant, any contributions made to the Plan and any related matching contributions will be invested in a qualified default investment alternative within the meaning of DOL Regulation Section 2550.404c-5.

The Plan provides for a Defined Contribution to the Plan. The Defined Contribution rate is 3.75% of eligible compensation plus 2% of eligible compensation in excess of the wage base for Plan years commencing on or after January 1, 2016. The Defined Contribution, as detailed in the Plan document, is allocated to each participant who is employed by Teva on the last work day of the last payroll period of the Plan year and has completed 1,000 hours of service during the Plan year. The Defined Contribution was \$25,822,433 and \$28,139,453 for the years ended December 31, 2021 and 2020, respectively. During 2022, the Company used forfeitures of \$3,877,607 to fund a portion of the 2021 Defined Contribution amount.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Participant Accounts

Each participant's account is credited with the participant's contribution, Teva's matching contribution, allocations of Teva's Defined Contribution and Plan earnings, and is charged with an allocation of administrative expenses. Allocations of the Defined Contribution are based on participant compensation, as defined in the Plan document. Allocations of Plan earnings and administrative expenses are based on participant account balances as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants are immediately vested in their contributions plus actual earnings thereon. Participants are 100 percent vested in Teva's Defined Contribution portion of their accounts plus actual earnings thereon after three years of credited service. With regards to Teva's matching contribution, participants who performed an hour or more of service prior to January 1, 2016, are immediately vested in the matching contribution. Participants who did not perform a minimum of an hour of service prior to January 1, 2016 become 100 percent vested in Teva's matching contribution portion of their accounts plus actual earnings thereon after three years of credited service.

Forfeited and Other Unallocated Accounts

Forfeited amounts, if any, may be used at the discretion of the Committee to restore accounts of reemployed participants, to fund matching contributions or the Defined Contribution or to pay Plan expenses (see Note 9). The unallocated forfeiture balance was \$4,947,647 and \$1,812,086 as of December 31, 2021 and 2020, respectively. During 2021 and 2020, approximately \$1,267,019 and \$2,437,507 of previously forfeited accounts were used to offset employer contributions, respectively.

Additionally, as of December 31, 2021 and 2020, the Plan had \$823 and \$2,509 of amounts in unallocated accounts which the Plan can use to pay for administrative expenses or allocate to participants. During the year ended December 31, 2021, \$1,704 was used to pay administrative expenses and no amounts were allocated to participants. During the year ended December 31, 2020, \$167,743 was used to pay administrative expenses and no amounts were allocated to participant accounts.

Investment Options

Participants direct the investment of their contributions into various mutual fund investment options and common collective trusts offered by the Plan and maintained by the trustee of the Plan. Participants direct the investment of their contributions into various fund investment options offered by the Plan in 1% increments. Investment performance is dependent on the investment experience, which is variable and not guaranteed. The Plan's exposure to credit loss in the event of nonperformance of investments managed by the trustee is limited to the carrying value of such investments.

Payment of Benefits

Distributions from the Plan are permitted under the following circumstances:

- Retirement or age 59-1/2;
- Death;
- Termination of employment;
- Hardship withdrawals.

A participant may elect to receive either a single lump sum payment or annual installments over a period not to exceed the joint life expectancy of the participant and the participant's designated beneficiary.

The beneficiary of a participant who is married on the date of the participant's death will be the surviving spouse. If the participant is not married or if the participant's surviving spouse consents to the designation of another beneficiary as detailed in the Plan document, the participant's designated beneficiary is entitled to the death benefits provided.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Notes Receivable from Participants

Plan participants may generally request loans for a minimum of \$1,000 up to a maximum generally equal to the lesser of \$50,000 or 50 percent of the participant's vested account balance. All loans are payable within five years, provided however, if the loan qualifies as a primary residence loan, the length of the loan shall not exceed ten years. Loans made under the provisions of a predecessor plan may remain outstanding until repaid in accordance with the terms of the predecessor plan. No more than two loans to a participant may be outstanding at any given time. The participant loans bear interest at rates which are commensurate with current interest rates charged by commercial lending institutions. Interest is charged to the account of the borrower. The loans are secured by the balance in the participant's account. Principal and interest are paid ratably through payroll deductions.

CARES Act Provisions Adopted

Effective March 27, 2020, the Plan adopted provisions under the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") including:

- Permitting qualified participants to receive coronavirus-related distributions. Eligible coronavirus-related distributions could be taken up to December 30, 2020 and may be repaid within three years; and
- Allowing for qualified participants to suspend loan repayments due through December 31, 2020. Suspended loan repayments resumed during 2021, and the loans were reamortized to extend the payoff period by one year and include accrued interest for the suspension period.

2. Summary of Significant Accounting Policies

The following are the significant accounting policies followed by the Plan:

Basis of Accounting

The financial statements of the Plan have been prepared on the accrual basis of accounting.

Investment Valuation and Income Recognition

Investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Plan's investment committee determines the Plan's valuation policies utilizing information provided by trustees, custodians and investment advisors. See Note 4 for discussion of fair value measurements.

Purchases and sales of investments are recorded on a trade-date basis. Interest income is accrued when earned. Dividend income is recorded on the ex-dividend date. Net appreciation in the fair value of investments includes the Plan's gains and losses on investments bought and sold as well as held during the year.

Notes Receivable from Participants

Notes receivable from participants (participant loans for Form 5500 reporting purposes) are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent participant loans are reclassified as distributions based upon the terms of the Plan document.

Contributions

Employer matching contributions are accrued based on eligible employee contributions which are generally recorded based on payroll withholdings.

Excess Contributions Payable

The Plan is required to return contributions received during the Plan year in excess of the Internal Revenue Code ("IRC") limits. At December 31, 2021 and 2020, the Plan had excess contributions. Such excess contributions are recorded as a liability with a corresponding reduction to contributions. The Plan distributed the 2021 and 2020 excess contributions to the applicable participants during 2022 and 2021, respectively.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires Plan management to make significant estimates and assumptions that affect the reported amounts of net assets available for benefits at the date of the financial statements and the changes in net assets available for benefits during the reporting period, and, when applicable, disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

Payment of Benefits

Benefits are recorded when paid.

Administrative Expenses

Certain expenses of maintaining the Plan are paid directly by Teva and are excluded from these financial statements. Fees related to the administration of notes receivable and other participant-specific fees are charged directly to the participant's account and are included in administrative expenses. Investment related expenses are included in net appreciation in fair value of investments. Certain other professional expenses of the Plan and its participants are partially offset through income generated from revenue sharing agreements (which is reported in the statements of changes in net assets available for benefits as other income, see Note 5).

Subsequent Events

The Plan has evaluated subsequent events through September 22, 2022, the date the financial statements were available to be issued.

3. Information Certified by a Qualified Institution

The Plan administrator having determined that it is permissible in the circumstances elected to have the audits of the Plan performed in accordance with ERISA section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Accordingly, as permitted under such election, the following information included in the accompanying financial statements and ERISA-required supplemental schedule of assets (held at end of year) was obtained or derived from information obtained by the Plan administrator and certified as complete and accurate by Fidelity Management Trust Company, trustee of the Plan and a qualified institution, in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA:

- Investments, at fair value, and notes receivable from participants, as shown in the statements of net assets available for benefits as of December 31, 2021 and 2020.
- Investment activity, including dividends, interest, net appreciation in fair value of investments, other income and interest income on notes receivable from participants, as shown in the statements of changes in net assets available for benefits for the years ended December 31, 2021 and 2020.
- The information for all registered investment companies (mutual funds), common collective trusts, and participant loans listed in the schedule of assets (held at end of year) as of December 31, 2021 as shown in the ERISA-required supplemental schedules.

4. Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described as follows:

- Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
- Level 2: Inputs to the valuation methodology include:
 - Quoted prices for similar assets or liabilities in active markets;

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in methodologies used at December 31, 2021 and 2020.

Mutual funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value ("NAV") and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Common collective trusts: Valued at the net asset value (NAV) or equivalent based on units of the common collective trust. The NAV, as provided by the custodian, is used as a practical expedient to estimate fair value. The NAV is generally based on the fair value of the underlying investments held by the common collective trust less its liabilities. This practical expedient is not used when it is determined to be probable that the common collective trust will sell the investment for an amount different than the reported NAV.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table sets forth by level, within the fair value hierarchy, the Plan's fair value measurements as of December 31, 2021:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments, at fair value:				
Mutual funds	\$ 281,153,531	\$ 281,153,531	\$ -	\$ -
Common collective trusts (*)	2,048,963,162	-	-	-
Total	<u>\$ 2,330,116,693</u>	<u>\$ 281,153,531</u>	<u>\$ -</u>	<u>\$ -</u>

The following table sets forth by level, within the fair value hierarchy, the Plan's fair value measurements as of December 31, 2020:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments, at fair value:				
Mutual funds	\$ 249,235,823	\$ 249,235,823	\$ -	\$ -
Common collective trusts (*)	1,869,938,589	-	-	-
Total	<u>\$ 2,119,174,412</u>	<u>\$ 249,235,823</u>	<u>\$ -</u>	<u>\$ -</u>

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

*In accordance with fair value measurement guidance, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented as investments in the statements of net assets available for benefits.

The following table sets forth additional disclosures for the fair value measurement of investments in certain entities that calculate net asset value per share (or its equivalent) as of December 31, 2021 and 2020.

<u>Investment Type</u>	<u>Fair Value</u>	<u>Fair Value</u>	<u>Unfunded</u>	<u>Redemption</u>	<u>Redemption</u>
	<u>December 31,</u>	<u>December 31,</u>			
	<u>2021</u>	<u>2020</u>	<u>Commitments</u>	<u>Frequency</u>	<u>Notice Period</u>
Common collective trusts	\$ 2,048,963,162	\$ 1,869,938,589	\$ -	Daily	Daily

The Plan is applying the practical expedient as of December 31, 2021 and 2020 to its common collective trusts.

The Plan's investment options include common collective trusts whose investment strategies are similar to target date funds, equity style funds and fixed income style funds. The objective of common collective trusts with target date strategies is to provide an age-based investment mix of stocks, bonds and short-term investments. The objectives of the common collective trusts invested in equity investments is to approximate the risk and return characterized by various indices; to seek long term capital appreciation; provide diversified exposure representative of various segments of the U.S. or foreign equity market; and/or to seek income. The objective of the common collective trusts invested in fixed income is to provide investment results that approximate the overall performance of certain bond indices and/or to provide a predictable rate of return while preserving the safety of capital and minimizing market risk. These common collective trusts are redeemable at net asset value under agreements with the underlying common collective trusts. However, it is possible that these redemption rights may be restricted by the common collective trusts in the future in accordance with underlying common collective trust agreements. Due to the nature of the investments held by the common collective trusts, changes in market conditions and the economic environment may significantly impact the net asset value of the common collective trusts, and consequently, the fair value of the Plan's interest in the common collective trusts. Furthermore, changes in the liquidity provisions of the common collective trusts may significantly impact the fair value of the Plan's interest in the common collective trusts.

The T. Rowe Price Stable Value Fund's (the "Stable Value Fund") investment objective is to maximize current income consistent with maintenance of principal and to provide for withdrawals for certain participant-initiated transactions under a retirement plan without penalty or adjustment. The Stable Value Fund invests principally in guaranteed investment contracts issued by insurance companies, investment contracts issued by banks, synthetic investment contracts issued by banks, insurance companies and other issuers, as well as other similar instruments. Participants' ownership of the Stable Value Fund is represented as units. Units are issued and redeemed daily at the Stable Value Fund's constant NAV of \$1 per unit. The Stable Value Fund allows for daily liquidity, with no additional days' notice required for redemption. It is the policy of the Stable Value Fund to use its best efforts to maintain a stable NAV of \$1 per unit, although there is no guarantee that the Stable Value Fund will be able to maintain this value.

The Stable Value Fund invests in assets (typically fixed income securities or bond funds, and may include derivative instruments such as futures contracts and swap agreements) and enters into "wrap" contracts issued by third parties and invests in cash equivalents represented by shares in a money market fund. Wrap contracts are designed to allow a stable value portfolio to maintain a constant NAV and protect a portfolio in extreme circumstances. In a typical wrap contract, the wrap issuer agrees to pay a portfolio the difference between the contract value and the market value of the underlying assets once the market value has been totally exhausted.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

The Stable Value Fund is unlikely to maintain a stable NAV if, for any reason, it cannot obtain or maintain wrap contracts covering all of its underlying assets that are not otherwise invested in money market funds.

5. Related-Party and Party in Interest Transactions

Plan investments include various investment options managed by affiliates of Fidelity Management Trust Company ("FMTC"). FMTC provides recordkeeping, trustee and custodial services to the Plan. Since FMTC is the trustee as defined by the Plan, administrative fees charged by FMTC that are paid from Plan assets qualify as party-in-interest transactions. These transactions are not, however, considered prohibited transactions under 29 CFR 408(b) of the ERISA regulations. Additionally, for participants who have elected to take a participant loan, the loans are secured by the respective participant's account balance. Fees paid by the Plan for the administrative services were \$644,417 and \$490,132 for the years ended December 31, 2021 and 2020, respectively. The Plan is interpreted, administered and operated by an Administrative Committee comprised entirely of executives of the Company.

FMTC or its affiliates generate income to the Plan through revenue sharing agreements. More specifically, FMTC or its affiliates may receive revenue from mutual fund and common collective trust service providers for services FMTC or its affiliates provide to the mutual funds and common collective trust. This revenue may be used to offset certain amounts owed to FMTC or its affiliates for administrative services to the Plan. If the revenue received by FMTC or its affiliates from such mutual fund or common collective trust service providers exceeds the amount owed as agreed to by FMTC and the Plan for administrative services, FMTC or its affiliates is to remit the excess to the Plan. Such amounts may be applied to pay Plan administrative expenses or allocated to the accounts of the participants. During the years ended December 31, 2021 and 2020, the related amounts deposited into the Plan and allocated directly to participant accounts were \$93,958 and \$38,896, respectively. The Plan or Plan Sponsor may make a payment to FMTC or its affiliates for administrative expenses not covered by revenue sharing.

During 2021, the Company failed to remit to the Plan's trustee certain employee contributions totaling \$4,024 within the period prescribed by the Department of Labor regulations. During 2022, the Company made contributions to the affected participants' accounts to compensate those participants for potential lost income due to the processing delays. The Company believes that these transactions do not affect the tax status of the Plan and took action prescribed by the regulations to remedy such errors.

6. Plan Termination

Although Teva has not expressed any intent to discontinue the Plan, Teva may do so at any time with consent of the trustee and subject to the provisions of ERISA. In the event of such discontinuance resulting in the termination of the Plan, participants would become 100 percent vested in their employer contributions and the net assets of the Plan would be distributed to Plan participants and beneficiaries in proportion to their respective account balances.

7. Tax Status

The Internal Revenue Service has determined and informed the Company by letter dated June 7, 2016, that the Plan was designed as a qualified trust in accordance with the applicable sections of the Internal Revenue Code (the "IRC"). The Plan has been amended since receiving the determination letter. However, the Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the IRC. Therefore, the Plan administrator believes the Plan, as amended, is qualified and the related trust is tax-exempt, and therefore, no provision for income taxes has been included in the Plan's financial statements.

Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. The plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021,

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan administrator believes it is no longer subject to income tax examinations for years prior to 2018.

8. Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits and the statements of changes in net assets available for benefits.

On December 5, 2019, a lawsuit was filed against the Company, its Board of Directors (the "Board") and Investment Committee (the "Committee"), and other defendants (collectively the "Defendants") regarding the investment options and fees associated with the Plan, under 29 U.S.C. sections 1109 and 1132(a)(2), Pinnell, et. al. v. Teva Pharmaceuticals USA, Inc. et. al., Case No. 19-5738 (E.D. Pennsylvania). The Plan itself is not named as a defendant. The complaint alleges that the Defendants breached the fiduciary duties of prudence and loyalty imposed by the federal Employee Retirement Income Security Act ("ERISA") by (1) selecting for the Plan certain investment options that allegedly charged "excessive" investment management fees when lower-cost/better-performing investments were available; and (2) allowing the Plans participants to pay excessive recordkeeping fees. On March 3, 2020, Defendants filed a motion to dismiss the Amended Complaint, seeking the dismissal with prejudice of all claims. The motion to dismiss was denied and the parties engaged in discovery on the limited issues of plaintiffs' individual claims and class certification. On June 11, 2021, the United States District Court for the Eastern District of Pennsylvania accepted and approved the parties' negotiated final settlement of all claims for \$2,550,000 without any admission of wrongdoing and thus closing out the litigation. In December 2021, \$1,011,242 was contributed to the Plan in accordance with the settlement agreement and is recorded as settlement proceeds on the statement of changes in net assets available for benefits for the year ended December 31, 2021. The settlement funds were allocated to the accounts of impacted participants in accordance with the amounts calculated by the settlement administrator. In accordance with the settlement agreement, class members without Plan accounts were paid directly by the settlement administrator a total of \$523,302. The remaining amount were allocated for class counsel fees and other fees.

9. Plan Amendments

During 2021, the Plan was amended in order to:

- Allow the Plan to use forfeitures to pay Plan expenses effective June 1, 2021;
- Incorporate provisions of the Setting Every Community Up for Retirement Enhancement Act (the "SECURE Act") and CARES Act;
- Change the requirement, effective January 1, 2022, from being employed on the last work day of the last payroll period of the Plan year to being employed by the employer on the last day of the Plan year in order to receive the Defined Contribution;
- Make other general administrative changes.

SUPPLEMENTAL SCHEDULES

Teva Pharmaceuticals Retirement Savings Plan
Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)
As of December 31, 2021

EIN: 22-1734359 Plan #004

(a)	(b) Identity of issue, borrower, lessor or similar party	(c) Description of investment including maturity date, rate of interest, collateral, par or maturity value	(e) Current value
	Registered Investment Companies (Mutual Funds):		
	Vanguard	Inflation Protected Bond Fund	\$ 21,427,531
	BlackRock	Total Return Fund	920,334
	Cohen & Steers	Real Estate Fund	30,267,946
*	Fidelity	Diversified International Fund	35,628,516
	T. Rowe Price	Large Capital Value Fund	63,500,911
	T. Rowe Price	U.S. Treasury Money Fund	4,948,470
	Vanguard	Wellington Fund	58,010,563
	Boston Trust	SMID Cap Fund	1,653,777
	Prudential	Jennison Small Company Fund	64,795,483
	Common Collective Trusts:		
	State Street	Retirement Income Fund	25,072,346
	State Street	Retirement 2020 Fund	69,125,227
	State Street	Retirement 2025 Fund	136,817,873
	State Street	Retirement 2030 Fund	220,138,259
	State Street	Retirement 2035 Fund	222,285,108
	State Street	Retirement 2040 Fund	199,044,196
	State Street	Retirement 2045 Fund	141,267,757
	State Street	Retirement 2050 Fund	59,421,758
	State Street	Retirement 2055 Fund	26,504,251
	State Street	Retirement 2060 Fund	7,719,265
	State Street	Retirement 2065 Fund	1,212,567
	State Street	Global All Cap Equity Fund	42,651,872
	State Street	Small/Mid Cap Index Fund	131,230,640
	State Street	S&P 500 Index Fund	282,096,740
	State Street	U.S. Bond Index Fund	50,438,497
	T. Rowe Price	Stable Value Fund	145,181,108
	T. Rowe Price	Large Cap Growth Fund	288,755,698
*	Participant Loans	Interest rates of 4.25% - 6.50% with maturities through 2041	19,528,596
			<u>\$ 2,349,645,289</u>

*: Party-in-interest

"Cost" is not required as all the investments are participant-directed. The cost value of participant loans is \$0.

The information in this schedule has been derived from information certified as to its completeness and accuracy by Fidelity Management Trust Company, a qualified institution.

Teva Pharmaceuticals Retirement Savings Plan
Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions
For the Year Ended December 31, 2021

	EIN 22-1734359 Plan #004			
Participant Contributions Transferred Late to Plan	Total that Constitute Nonexempt Prohibited Transactions			Total Fully Corrected Under VFCP and PTE 2002-51
Check Here if Late Participant Loan Repayments are included:[]	Contributions Not Corrected	Contributions Corrected Outside VFCP	Contributions Pending Correction in VFCP	
2021* \$4,024	\$4,024	-	-	-

- * During 2021, the Company failed to remit to the Plan's trustee certain employee contributions totaling \$4,024 within the period prescribed by the Department of Labor regulations. During 2022, the Company made contributions to the affected participants' accounts to compensate those participants for potential lost income due to the processing delays. The Company believes that these transactions do not affect the tax status of the Plan and took action prescribed by the regulations to remedy such errors.

TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN

**Financial Statements
As of and for the Years Ended
December 31, 2021 and 2020
And
Supplemental Schedules
As of and For the Year Ended
December 31, 2021**

Teva Pharmaceuticals Retirement Savings Plan Index

	Page(s)
Independent Auditor's Report	1 - 3
Financial Statements:	
Statements of Net Assets Available for Benefits	4
Statements of Changes in Net Assets Available for Benefits	5
Notes to Financial Statements	6 - 13
Supplemental Schedules:	
Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)	S.1
Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions	S.2
• The supplemental schedules included are presented for purposes of additional analysis and are not a required part of the financial statements but are required by the Employee Retirement Income Security Act of 1974, as amended ("ERISA"). Other schedules required by section 2520.103-10 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable.	

INDEPENDENT AUDITOR'S REPORT

To the Plan Administrator of the Teva Pharmaceuticals Retirement Savings Plan

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements

We have performed an audit of the accompanying financial statements of the Teva Pharmaceuticals Retirement Savings Plan, an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C) ("ERISA Section 103(a)(3)(C) audit"). The financial statements comprise the statement of net assets available for benefits as of December 31, 2021, and the related statement of changes in net assets available for benefits for the year then ended, and the related notes to the financial statements ("2021 Financial Statements").

Plan management, having determined it is permissible in the circumstances, has elected to have the audit of the 2021 Financial Statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the Plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Plan management has obtained a certification from a qualified institution as of and for the year ended December 31, 2021, stating that the certified investment information, as described in Note 3 to the financial statements, is complete and accurate.

Opinion on the 2021 Financial Statements

In our opinion, based on our audit and on the procedures performed as described in the *Auditor's Responsibilities for the Audit of the 2021 Financial Statements* section:

- the amounts and disclosures in the 2021 Financial Statements referred to above, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- the information in the 2021 Financial Statements referred to above related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that Plan management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion on the 2021 Financial Statements

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the 2021 Financial Statements* section of our report. We are required to be independent of the Teva Pharmaceuticals Retirement Savings Plan and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Plan Management for the Financial Statements

Plan management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Plan management's election of the ERISA Section 103(a)(3)(C) audit does not affect Plan management's responsibility for the financial statements.

In preparing the financial statements, Plan management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Teva Pharmaceuticals Retirement Savings Plan's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Plan management is also responsible for maintaining a current Plan instrument, including all Plan amendments; administering the Plan; and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditor's Responsibilities for the Audit of the 2021 Financial Statements

Except as described in the *Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements* section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Teva Pharmaceuticals Retirement Savings Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by Plan management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Teva Pharmaceuticals Retirement Savings Plan's ability to continue as a going concern for a reasonable period of time.

Our audit did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the 2021 Financial Statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matter—2021 Supplemental Schedules Required by ERISA

The supplemental Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year) as of December 31, 2021, and Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions for the year ended December 31, 2021, are presented for purposes of additional analysis and are not a required part of the financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of Plan management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including their form and content, are presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- the form and content of the supplemental schedules, other than the information in the supplemental schedules that agreed to or is derived from the certified investment information, are presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- the information in the supplemental schedules related to assets held by and certified to by a qualified institution agrees to or is derived from, in all material respects, the information prepared and certified by an institution that Plan management determined meets the requirements of ERISA Section 103(a)(3)(C).

Other Matter—Auditor's Report on the 2020 Financial Statements

We were engaged to audit the 2020 financial statements of the Teva Pharmaceuticals Retirement Savings Plan. As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA, the Plan administrator instructed us not to perform and we did not perform any auditing procedures with respect to the information certified by a qualified institution. In our report dated September 29, 2021, we indicated that (a) because of the significance of the information that we did not audit, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion and accordingly, we did not express an opinion on the 2020 financial statements, and (b) the form and content of the information included in the 2020 financial statements other than that derived from the certified information were presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

Touille & Associates, LLC

September 22, 2022

Teva Pharmaceuticals Retirement Savings Plan
Statements of Net Assets Available for Benefits
As of December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Assets:		
Investments, at fair value	\$ 2,330,116,693	\$ 2,119,174,412
Receivables:		
Employee contributions	1,331,477	1,436,115
Employer contributions	22,825,731	29,710,005
Notes receivable from participants	19,528,596	21,604,568
Total receivables	<u>43,685,804</u>	<u>52,750,688</u>
Total assets	2,373,802,497	2,171,925,100
Liabilities:		
Excess contributions payable	<u>22,055</u>	<u>20,507</u>
Total liabilities	<u>22,055</u>	<u>20,507</u>
Net assets available for benefits	<u>\$ 2,373,780,442</u>	<u>\$ 2,171,904,593</u>

The accompanying notes are an integral part of these financial statements.

Teva Pharmaceuticals Retirement Savings Plan
Statements of Changes in Net Assets Available for Benefits
For the Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Additions to net assets attributed to:		
Investment income:		
Net appreciation in fair value of investments	\$ 291,068,831	\$ 297,670,428
Dividends	31,057,686	16,731,689
Interest	2,665,176	617,824
Other income	93,958	38,896
Investment income	<u>324,885,651</u>	<u>315,058,837</u>
Interest income on notes receivable from participants	1,097,508	1,287,491
Contributions:		
Employee contributions	60,564,322	62,608,099
Employer contributions	59,070,682	68,160,559
Rollover contributions	14,599,386	12,545,560
Total contributions	<u>134,234,390</u>	<u>143,314,218</u>
Proceeds from settlement (see Note 8)	<u>1,011,242</u>	<u>-</u>
Total additions	461,228,791	459,660,546
Deductions from net assets attributed to:		
Benefits paid to participants	258,708,525	252,119,837
Administrative expenses	644,417	490,132
Total deductions	<u>259,352,942</u>	<u>252,609,969</u>
Net increase in net assets available for benefits	201,875,849	207,050,577
Net assets available for benefits		
Beginning of year	2,171,904,593	1,964,854,016
End of year	<u>\$ 2,373,780,442</u>	<u>\$ 2,171,904,593</u>

The accompanying notes are an integral part of these financial statements.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

1. Description of Plan

The following description of the Teva Pharmaceuticals Retirement Savings Plan (the “Plan”) provides only general information. Participants should refer to the Summary Plan Description and the Plan document for a more complete description of the Plan’s provisions. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”).

General

The Plan is a defined contribution plan sponsored by Teva Pharmaceuticals USA, Inc. (“Teva” or the “Company”). Employees covered by a collective bargaining agreement, nonresident aliens, leased employees, employees rendering services in Puerto Rico who are receiving income that is taxable under the Puerto Rico Internal Revenue Code of 2011, as amended, and temporary or independent contractors are generally excluded from participating in the Plan. Employees are able to enroll in the Plan beginning the first day of each calendar month after their date of hire. Effective January 1, 2019, the Plan was amended and restated. Fidelity Management Trust Company is the trustee of the Plan.

Contributions

Participants may contribute 1% to 75% of compensation as a tax-deferred contribution or as a Roth contribution, as defined in the Plan. A participant may not elect to make both tax-deferred contributions and Roth contributions with respect to the same payroll period. In the event a participant fails to designate whether his or her elective contributions are to be characterized as tax-deferred or Roth contributions, such elective contributions will be characterized as tax-deferred. Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans.

The Plan provides for employer matching contributions which equal 100% of the first 6% of employee contributions.

As detailed in the Plan document, new employees are subject to automatic enrollment and will be deemed to have elected to make tax-deferred contributions to the Plan at a rate equal to 4% of their eligible compensation. Such tax-deferred contributions commence with respect to the first payday that occurs on the date with or following the 45th day following the date the employee is eligible to participate in the Plan. The participant will be provided a notice describing the terms and conditions of automatic enrollment and has until the end of the 45-day period to elect not to make automatic tax-deferred contributions, to modify the amount of such tax-deferred contributions, or to make Roth contributions. Such participant may withdraw their contributions, plus any income and minus any losses by notifying the Teva Pharmaceuticals USA, Inc. Compensation and Employee Benefits Committee (the “Committee”) during the 90-day period following the first contribution. In the absence of investment direction by the participant, any contributions made to the Plan and any related matching contributions will be invested in a qualified default investment alternative within the meaning of DOL Regulation Section 2550.404c-5.

The Plan provides for a Defined Contribution to the Plan. The Defined Contribution rate is 3.75% of eligible compensation plus 2% of eligible compensation in excess of the wage base for Plan years commencing on or after January 1, 2016. The Defined Contribution, as detailed in the Plan document, is allocated to each participant who is employed by Teva on the last work day of the last payroll period of the Plan year and has completed 1,000 hours of service during the Plan year. The Defined Contribution was \$25,822,433 and \$28,139,453 for the years ended December 31, 2021 and 2020, respectively. During 2022, the Company used forfeitures of \$3,877,607 to fund a portion of the 2021 Defined Contribution amount.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Participant Accounts

Each participant's account is credited with the participant's contribution, Teva's matching contribution, allocations of Teva's Defined Contribution and Plan earnings, and is charged with an allocation of administrative expenses. Allocations of the Defined Contribution are based on participant compensation, as defined in the Plan document. Allocations of Plan earnings and administrative expenses are based on participant account balances as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants are immediately vested in their contributions plus actual earnings thereon. Participants are 100 percent vested in Teva's Defined Contribution portion of their accounts plus actual earnings thereon after three years of credited service. With regards to Teva's matching contribution, participants who performed an hour or more of service prior to January 1, 2016, are immediately vested in the matching contribution. Participants who did not perform a minimum of an hour of service prior to January 1, 2016 become 100 percent vested in Teva's matching contribution portion of their accounts plus actual earnings thereon after three years of credited service.

Forfeited and Other Unallocated Accounts

Forfeited amounts, if any, may be used at the discretion of the Committee to restore accounts of reemployed participants, to fund matching contributions or the Defined Contribution or to pay Plan expenses (see Note 9). The unallocated forfeiture balance was \$4,947,647 and \$1,812,086 as of December 31, 2021 and 2020, respectively. During 2021 and 2020, approximately \$1,267,019 and \$2,437,507 of previously forfeited accounts were used to offset employer contributions, respectively.

Additionally, as of December 31, 2021 and 2020, the Plan had \$823 and \$2,509 of amounts in unallocated accounts which the Plan can use to pay for administrative expenses or allocate to participants. During the year ended December 31, 2021, \$1,704 was used to pay administrative expenses and no amounts were allocated to participants. During the year ended December 31, 2020, \$167,743 was used to pay administrative expenses and no amounts were allocated to participant accounts.

Investment Options

Participants direct the investment of their contributions into various mutual fund investment options and common collective trusts offered by the Plan and maintained by the trustee of the Plan. Participants direct the investment of their contributions into various fund investment options offered by the Plan in 1% increments. Investment performance is dependent on the investment experience, which is variable and not guaranteed. The Plan's exposure to credit loss in the event of nonperformance of investments managed by the trustee is limited to the carrying value of such investments.

Payment of Benefits

Distributions from the Plan are permitted under the following circumstances:

- Retirement or age 59-1/2;
- Death;
- Termination of employment;
- Hardship withdrawals.

A participant may elect to receive either a single lump sum payment or annual installments over a period not to exceed the joint life expectancy of the participant and the participant's designated beneficiary.

The beneficiary of a participant who is married on the date of the participant's death will be the surviving spouse. If the participant is not married or if the participant's surviving spouse consents to the designation of another beneficiary as detailed in the Plan document, the participant's designated beneficiary is entitled to the death benefits provided.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Notes Receivable from Participants

Plan participants may generally request loans for a minimum of \$1,000 up to a maximum generally equal to the lesser of \$50,000 or 50 percent of the participant's vested account balance. All loans are payable within five years, provided however, if the loan qualifies as a primary residence loan, the length of the loan shall not exceed ten years. Loans made under the provisions of a predecessor plan may remain outstanding until repaid in accordance with the terms of the predecessor plan. No more than two loans to a participant may be outstanding at any given time. The participant loans bear interest at rates which are commensurate with current interest rates charged by commercial lending institutions. Interest is charged to the account of the borrower. The loans are secured by the balance in the participant's account. Principal and interest are paid ratably through payroll deductions.

CARES Act Provisions Adopted

Effective March 27, 2020, the Plan adopted provisions under the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") including:

- Permitting qualified participants to receive coronavirus-related distributions. Eligible coronavirus-related distributions could be taken up to December 30, 2020 and may be repaid within three years; and
- Allowing for qualified participants to suspend loan repayments due through December 31, 2020. Suspended loan repayments resumed during 2021, and the loans were reamortized to extend the payoff period by one year and include accrued interest for the suspension period.

2. Summary of Significant Accounting Policies

The following are the significant accounting policies followed by the Plan:

Basis of Accounting

The financial statements of the Plan have been prepared on the accrual basis of accounting.

Investment Valuation and Income Recognition

Investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Plan's investment committee determines the Plan's valuation policies utilizing information provided by trustees, custodians and investment advisors. See Note 4 for discussion of fair value measurements.

Purchases and sales of investments are recorded on a trade-date basis. Interest income is accrued when earned. Dividend income is recorded on the ex-dividend date. Net appreciation in the fair value of investments includes the Plan's gains and losses on investments bought and sold as well as held during the year.

Notes Receivable from Participants

Notes receivable from participants (participant loans for Form 5500 reporting purposes) are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent participant loans are reclassified as distributions based upon the terms of the Plan document.

Contributions

Employer matching contributions are accrued based on eligible employee contributions which are generally recorded based on payroll withholdings.

Excess Contributions Payable

The Plan is required to return contributions received during the Plan year in excess of the Internal Revenue Code ("IRC") limits. At December 31, 2021 and 2020, the Plan had excess contributions. Such excess contributions are recorded as a liability with a corresponding reduction to contributions. The Plan distributed the 2021 and 2020 excess contributions to the applicable participants during 2022 and 2021, respectively.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires Plan management to make significant estimates and assumptions that affect the reported amounts of net assets available for benefits at the date of the financial statements and the changes in net assets available for benefits during the reporting period, and, when applicable, disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

Payment of Benefits

Benefits are recorded when paid.

Administrative Expenses

Certain expenses of maintaining the Plan are paid directly by Teva and are excluded from these financial statements. Fees related to the administration of notes receivable and other participant-specific fees are charged directly to the participant's account and are included in administrative expenses. Investment related expenses are included in net appreciation in fair value of investments. Certain other professional expenses of the Plan and its participants are partially offset through income generated from revenue sharing agreements (which is reported in the statements of changes in net assets available for benefits as other income, see Note 5).

Subsequent Events

The Plan has evaluated subsequent events through September 22, 2022, the date the financial statements were available to be issued.

3. Information Certified by a Qualified Institution

The Plan administrator having determined that it is permissible in the circumstances elected to have the audits of the Plan performed in accordance with ERISA section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Accordingly, as permitted under such election, the following information included in the accompanying financial statements and ERISA-required supplemental schedule of assets (held at end of year) was obtained or derived from information obtained by the Plan administrator and certified as complete and accurate by Fidelity Management Trust Company, trustee of the Plan and a qualified institution, in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA:

- Investments, at fair value, and notes receivable from participants, as shown in the statements of net assets available for benefits as of December 31, 2021 and 2020.
- Investment activity, including dividends, interest, net appreciation in fair value of investments, other income and interest income on notes receivable from participants, as shown in the statements of changes in net assets available for benefits for the years ended December 31, 2021 and 2020.
- The information for all registered investment companies (mutual funds), common collective trusts, and participant loans listed in the schedule of assets (held at end of year) as of December 31, 2021 as shown in the ERISA-required supplemental schedules.

4. Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described as follows:

- Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
- Level 2: Inputs to the valuation methodology include:
 - Quoted prices for similar assets or liabilities in active markets;

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in methodologies used at December 31, 2021 and 2020.

Mutual funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value ("NAV") and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Common collective trusts: Valued at the net asset value (NAV) or equivalent based on units of the common collective trust. The NAV, as provided by the custodian, is used as a practical expedient to estimate fair value. The NAV is generally based on the fair value of the underlying investments held by the common collective trust less its liabilities. This practical expedient is not used when it is determined to be probable that the common collective trust will sell the investment for an amount different than the reported NAV.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table sets forth by level, within the fair value hierarchy, the Plan's fair value measurements as of December 31, 2021:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments, at fair value:				
Mutual funds	\$ 281,153,531	\$ 281,153,531	\$ -	\$ -
Common collective trusts (*)	2,048,963,162	-	-	-
Total	<u>\$ 2,330,116,693</u>	<u>\$ 281,153,531</u>	<u>\$ -</u>	<u>\$ -</u>

The following table sets forth by level, within the fair value hierarchy, the Plan's fair value measurements as of December 31, 2020:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments, at fair value:				
Mutual funds	\$ 249,235,823	\$ 249,235,823	\$ -	\$ -
Common collective trusts (*)	1,869,938,589	-	-	-
Total	<u>\$ 2,119,174,412</u>	<u>\$ 249,235,823</u>	<u>\$ -</u>	<u>\$ -</u>

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

*In accordance with fair value measurement guidance, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented as investments in the statements of net assets available for benefits.

The following table sets forth additional disclosures for the fair value measurement of investments in certain entities that calculate net asset value per share (or its equivalent) as of December 31, 2021 and 2020.

<u>Investment Type</u>	<u>Fair Value</u>	<u>Fair Value</u>	<u>Unfunded</u>	<u>Redemption</u>	<u>Redemption</u>
	<u>December 31,</u>	<u>December 31,</u>			
	<u>2021</u>	<u>2020</u>	<u>Commitments</u>	<u>Frequency</u>	<u>Notice Period</u>
Common collective trusts	\$ 2,048,963,162	\$ 1,869,938,589	\$ -	Daily	Daily

The Plan is applying the practical expedient as of December 31, 2021 and 2020 to its common collective trusts.

The Plan's investment options include common collective trusts whose investment strategies are similar to target date funds, equity style funds and fixed income style funds. The objective of common collective trusts with target date strategies is to provide an age-based investment mix of stocks, bonds and short-term investments. The objectives of the common collective trusts invested in equity investments is to approximate the risk and return characterized by various indices; to seek long term capital appreciation; provide diversified exposure representative of various segments of the U.S. or foreign equity market; and/or to seek income. The objective of the common collective trusts invested in fixed income is to provide investment results that approximate the overall performance of certain bond indices and/or to provide a predictable rate of return while preserving the safety of capital and minimizing market risk. These common collective trusts are redeemable at net asset value under agreements with the underlying common collective trusts. However, it is possible that these redemption rights may be restricted by the common collective trusts in the future in accordance with underlying common collective trust agreements. Due to the nature of the investments held by the common collective trusts, changes in market conditions and the economic environment may significantly impact the net asset value of the common collective trusts, and consequently, the fair value of the Plan's interest in the common collective trusts. Furthermore, changes in the liquidity provisions of the common collective trusts may significantly impact the fair value of the Plan's interest in the common collective trusts.

The T. Rowe Price Stable Value Fund's (the "Stable Value Fund") investment objective is to maximize current income consistent with maintenance of principal and to provide for withdrawals for certain participant-initiated transactions under a retirement plan without penalty or adjustment. The Stable Value Fund invests principally in guaranteed investment contracts issued by insurance companies, investment contracts issued by banks, synthetic investment contracts issued by banks, insurance companies and other issuers, as well as other similar instruments. Participants' ownership of the Stable Value Fund is represented as units. Units are issued and redeemed daily at the Stable Value Fund's constant NAV of \$1 per unit. The Stable Value Fund allows for daily liquidity, with no additional days' notice required for redemption. It is the policy of the Stable Value Fund to use its best efforts to maintain a stable NAV of \$1 per unit, although there is no guarantee that the Stable Value Fund will be able to maintain this value.

The Stable Value Fund invests in assets (typically fixed income securities or bond funds, and may include derivative instruments such as futures contracts and swap agreements) and enters into "wrap" contracts issued by third parties and invests in cash equivalents represented by shares in a money market fund. Wrap contracts are designed to allow a stable value portfolio to maintain a constant NAV and protect a portfolio in extreme circumstances. In a typical wrap contract, the wrap issuer agrees to pay a portfolio the difference between the contract value and the market value of the underlying assets once the market value has been totally exhausted.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

The Stable Value Fund is unlikely to maintain a stable NAV if, for any reason, it cannot obtain or maintain wrap contracts covering all of its underlying assets that are not otherwise invested in money market funds.

5. Related-Party and Party in Interest Transactions

Plan investments include various investment options managed by affiliates of Fidelity Management Trust Company ("FMTC"). FMTC provides recordkeeping, trustee and custodial services to the Plan. Since FMTC is the trustee as defined by the Plan, administrative fees charged by FMTC that are paid from Plan assets qualify as party-in-interest transactions. These transactions are not, however, considered prohibited transactions under 29 CFR 408(b) of the ERISA regulations. Additionally, for participants who have elected to take a participant loan, the loans are secured by the respective participant's account balance. Fees paid by the Plan for the administrative services were \$644,417 and \$490,132 for the years ended December 31, 2021 and 2020, respectively. The Plan is interpreted, administered and operated by an Administrative Committee comprised entirely of executives of the Company.

FMTC or its affiliates generate income to the Plan through revenue sharing agreements. More specifically, FMTC or its affiliates may receive revenue from mutual fund and common collective trust service providers for services FMTC or its affiliates provide to the mutual funds and common collective trust. This revenue may be used to offset certain amounts owed to FMTC or its affiliates for administrative services to the Plan. If the revenue received by FMTC or its affiliates from such mutual fund or common collective trust service providers exceeds the amount owed as agreed to by FMTC and the Plan for administrative services, FMTC or its affiliates is to remit the excess to the Plan. Such amounts may be applied to pay Plan administrative expenses or allocated to the accounts of the participants. During the years ended December 31, 2021 and 2020, the related amounts deposited into the Plan and allocated directly to participant accounts were \$93,958 and \$38,896, respectively. The Plan or Plan Sponsor may make a payment to FMTC or its affiliates for administrative expenses not covered by revenue sharing.

During 2021, the Company failed to remit to the Plan's trustee certain employee contributions totaling \$4,024 within the period prescribed by the Department of Labor regulations. During 2022, the Company made contributions to the affected participants' accounts to compensate those participants for potential lost income due to the processing delays. The Company believes that these transactions do not affect the tax status of the Plan and took action prescribed by the regulations to remedy such errors.

6. Plan Termination

Although Teva has not expressed any intent to discontinue the Plan, Teva may do so at any time with consent of the trustee and subject to the provisions of ERISA. In the event of such discontinuance resulting in the termination of the Plan, participants would become 100 percent vested in their employer contributions and the net assets of the Plan would be distributed to Plan participants and beneficiaries in proportion to their respective account balances.

7. Tax Status

The Internal Revenue Service has determined and informed the Company by letter dated June 7, 2016, that the Plan was designed as a qualified trust in accordance with the applicable sections of the Internal Revenue Code (the "IRC"). The Plan has been amended since receiving the determination letter. However, the Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the IRC. Therefore, the Plan administrator believes the Plan, as amended, is qualified and the related trust is tax-exempt, and therefore, no provision for income taxes has been included in the Plan's financial statements.

Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. The plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021,

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan administrator believes it is no longer subject to income tax examinations for years prior to 2018.

8. Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits and the statements of changes in net assets available for benefits.

On December 5, 2019, a lawsuit was filed against the Company, its Board of Directors (the "Board") and Investment Committee (the "Committee"), and other defendants (collectively the "Defendants") regarding the investment options and fees associated with the Plan, under 29 U.S.C. sections 1109 and 1132(a)(2), Pinnell, et. al. v. Teva Pharmaceuticals USA, Inc. et. al., Case No. 19-5738 (E.D. Pennsylvania). The Plan itself is not named as a defendant. The complaint alleges that the Defendants breached the fiduciary duties of prudence and loyalty imposed by the federal Employee Retirement Income Security Act ("ERISA") by (1) selecting for the Plan certain investment options that allegedly charged "excessive" investment management fees when lower-cost/better-performing investments were available; and (2) allowing the Plans participants to pay excessive recordkeeping fees. On March 3, 2020, Defendants filed a motion to dismiss the Amended Complaint, seeking the dismissal with prejudice of all claims. The motion to dismiss was denied and the parties engaged in discovery on the limited issues of plaintiffs' individual claims and class certification. On June 11, 2021, the United States District Court for the Eastern District of Pennsylvania accepted and approved the parties' negotiated final settlement of all claims for \$2,550,000 without any admission of wrongdoing and thus closing out the litigation. In December 2021, \$1,011,242 was contributed to the Plan in accordance with the settlement agreement and is recorded as settlement proceeds on the statement of changes in net assets available for benefits for the year ended December 31, 2021. The settlement funds were allocated to the accounts of impacted participants in accordance with the amounts calculated by the settlement administrator. In accordance with the settlement agreement, class members without Plan accounts were paid directly by the settlement administrator a total of \$523,302. The remaining amount were allocated for class counsel fees and other fees.

9. Plan Amendments

During 2021, the Plan was amended in order to:

- Allow the Plan to use forfeitures to pay Plan expenses effective June 1, 2021;
- Incorporate provisions of the Setting Every Community Up for Retirement Enhancement Act (the "SECURE Act") and CARES Act;
- Change the requirement, effective January 1, 2022, from being employed on the last work day of the last payroll period of the Plan year to being employed by the employer on the last day of the Plan year in order to receive the Defined Contribution;
- Make other general administrative changes.

SUPPLEMENTAL SCHEDULES

Teva Pharmaceuticals Retirement Savings Plan
Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)
As of December 31, 2021

EIN: 22-1734359 Plan #004

(a)	(b) Identity of issue, borrower, lessor or similar party	(c) Description of investment including maturity date, rate of interest, collateral, par or maturity value	(e) Current value
	Registered Investment Companies (Mutual Funds):		
	Vanguard	Inflation Protected Bond Fund	\$ 21,427,531
	BlackRock	Total Return Fund	920,334
	Cohen & Steers	Real Estate Fund	30,267,946
*	Fidelity	Diversified International Fund	35,628,516
	T. Rowe Price	Large Capital Value Fund	63,500,911
	T. Rowe Price	U.S. Treasury Money Fund	4,948,470
	Vanguard	Wellington Fund	58,010,563
	Boston Trust	SMID Cap Fund	1,653,777
	Prudential	Jennison Small Company Fund	64,795,483
	Common Collective Trusts:		
	State Street	Retirement Income Fund	25,072,346
	State Street	Retirement 2020 Fund	69,125,227
	State Street	Retirement 2025 Fund	136,817,873
	State Street	Retirement 2030 Fund	220,138,259
	State Street	Retirement 2035 Fund	222,285,108
	State Street	Retirement 2040 Fund	199,044,196
	State Street	Retirement 2045 Fund	141,267,757
	State Street	Retirement 2050 Fund	59,421,758
	State Street	Retirement 2055 Fund	26,504,251
	State Street	Retirement 2060 Fund	7,719,265
	State Street	Retirement 2065 Fund	1,212,567
	State Street	Global All Cap Equity Fund	42,651,872
	State Street	Small/Mid Cap Index Fund	131,230,640
	State Street	S&P 500 Index Fund	282,096,740
	State Street	U.S. Bond Index Fund	50,438,497
	T. Rowe Price	Stable Value Fund	145,181,108
	T. Rowe Price	Large Cap Growth Fund	288,755,698
*	Participant Loans	Interest rates of 4.25% - 6.50% with maturities through 2041	19,528,596
			<u>\$ 2,349,645,289</u>

*: Party-in-interest

"Cost" is not required as all the investments are participant-directed. The cost value of participant loans is \$0.

The information in this schedule has been derived from information certified as to its completeness and accuracy by Fidelity Management Trust Company, a qualified institution.

Teva Pharmaceuticals Retirement Savings Plan
Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions
For the Year Ended December 31, 2021

	EIN 22-1734359 Plan #004			
Participant Contributions Transferred Late to Plan	Total that Constitute Nonexempt Prohibited Transactions			Total Fully Corrected Under VFCP and PTE 2002-51
Check Here if Late Participant Loan Repayments are included:[]	Contributions Not Corrected	Contributions Corrected Outside VFCP	Contributions Pending Correction in VFCP	
2021* \$4,024	\$4,024	-	-	-

- * During 2021, the Company failed to remit to the Plan's trustee certain employee contributions totaling \$4,024 within the period prescribed by the Department of Labor regulations. During 2022, the Company made contributions to the affected participants' accounts to compensate those participants for potential lost income due to the processing delays. The Company believes that these transactions do not affect the tax status of the Plan and took action prescribed by the regulations to remedy such errors.

TEVA PHARMACEUTICALS RETIREMENT SAVINGS PLAN

**Financial Statements
As of and for the Years Ended
December 31, 2021 and 2020
And
Supplemental Schedules
As of and For the Year Ended
December 31, 2021**

Teva Pharmaceuticals Retirement Savings Plan Index

	Page(s)
Independent Auditor's Report	1 - 3
Financial Statements:	
Statements of Net Assets Available for Benefits	4
Statements of Changes in Net Assets Available for Benefits	5
Notes to Financial Statements	6 - 13
Supplemental Schedules:	
Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)	S.1
Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions	S.2
• The supplemental schedules included are presented for purposes of additional analysis and are not a required part of the financial statements but are required by the Employee Retirement Income Security Act of 1974, as amended ("ERISA"). Other schedules required by section 2520.103-10 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable.	

INDEPENDENT AUDITOR'S REPORT

To the Plan Administrator of the Teva Pharmaceuticals Retirement Savings Plan

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements

We have performed an audit of the accompanying financial statements of the Teva Pharmaceuticals Retirement Savings Plan, an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 ("ERISA"), as permitted by ERISA Section 103(a)(3)(C) ("ERISA Section 103(a)(3)(C) audit"). The financial statements comprise the statement of net assets available for benefits as of December 31, 2021, and the related statement of changes in net assets available for benefits for the year then ended, and the related notes to the financial statements ("2021 Financial Statements").

Plan management, having determined it is permissible in the circumstances, has elected to have the audit of the 2021 Financial Statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audit need not extend to any statements or information related to assets held for investment of the Plan ("investment information") by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA ("qualified institution").

Plan management has obtained a certification from a qualified institution as of and for the year ended December 31, 2021, stating that the certified investment information, as described in Note 3 to the financial statements, is complete and accurate.

Opinion on the 2021 Financial Statements

In our opinion, based on our audit and on the procedures performed as described in the *Auditor's Responsibilities for the Audit of the 2021 Financial Statements* section:

- the amounts and disclosures in the 2021 Financial Statements referred to above, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- the information in the 2021 Financial Statements referred to above related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that Plan management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion on the 2021 Financial Statements

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the 2021 Financial Statements* section of our report. We are required to be independent of the Teva Pharmaceuticals Retirement Savings Plan and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Plan Management for the Financial Statements

Plan management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Plan management's election of the ERISA Section 103(a)(3)(C) audit does not affect Plan management's responsibility for the financial statements.

In preparing the financial statements, Plan management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Teva Pharmaceuticals Retirement Savings Plan's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Plan management is also responsible for maintaining a current Plan instrument, including all Plan amendments; administering the Plan; and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditor's Responsibilities for the Audit of the 2021 Financial Statements

Except as described in the *Scope and Nature of the ERISA Section 103(a)(3)(C) Audit for the 2021 Financial Statements* section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Teva Pharmaceuticals Retirement Savings Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by Plan management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Teva Pharmaceuticals Retirement Savings Plan's ability to continue as a going concern for a reasonable period of time.

Our audit did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the 2021 Financial Statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Matter—2021 Supplemental Schedules Required by ERISA

The supplemental Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year) as of December 31, 2021, and Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions for the year ended December 31, 2021, are presented for purposes of additional analysis and are not a required part of the financial statements but are supplementary information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of Plan management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including their form and content, are presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- the form and content of the supplemental schedules, other than the information in the supplemental schedules that agreed to or is derived from the certified investment information, are presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- the information in the supplemental schedules related to assets held by and certified to by a qualified institution agrees to or is derived from, in all material respects, the information prepared and certified by an institution that Plan management determined meets the requirements of ERISA Section 103(a)(3)(C).

Other Matter—Auditor's Report on the 2020 Financial Statements

We were engaged to audit the 2020 financial statements of the Teva Pharmaceuticals Retirement Savings Plan. As permitted by 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA, the Plan administrator instructed us not to perform and we did not perform any auditing procedures with respect to the information certified by a qualified institution. In our report dated September 29, 2021, we indicated that (a) because of the significance of the information that we did not audit, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion and accordingly, we did not express an opinion on the 2020 financial statements, and (b) the form and content of the information included in the 2020 financial statements other than that derived from the certified information were presented in compliance with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

Torillo & Associates, LLP

September 22, 2022

Teva Pharmaceuticals Retirement Savings Plan
Statements of Net Assets Available for Benefits
As of December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Assets:		
Investments, at fair value	\$ 2,330,116,693	\$ 2,119,174,412
Receivables:		
Employee contributions	1,331,477	1,436,115
Employer contributions	22,825,731	29,710,005
Notes receivable from participants	19,528,596	21,604,568
Total receivables	<u>43,685,804</u>	<u>52,750,688</u>
Total assets	2,373,802,497	2,171,925,100
Liabilities:		
Excess contributions payable	<u>22,055</u>	<u>20,507</u>
Total liabilities	<u>22,055</u>	<u>20,507</u>
Net assets available for benefits	<u>\$ 2,373,780,442</u>	<u>\$ 2,171,904,593</u>

The accompanying notes are an integral part of these financial statements.

Teva Pharmaceuticals Retirement Savings Plan
Statements of Changes in Net Assets Available for Benefits
For the Years Ended December 31, 2021 and 2020

	<u>2021</u>	<u>2020</u>
Additions to net assets attributed to:		
Investment income:		
Net appreciation in fair value of investments	\$ 291,068,831	\$ 297,670,428
Dividends	31,057,686	16,731,689
Interest	2,665,176	617,824
Other income	93,958	38,896
Investment income	<u>324,885,651</u>	<u>315,058,837</u>
Interest income on notes receivable from participants	1,097,508	1,287,491
Contributions:		
Employee contributions	60,564,322	62,608,099
Employer contributions	59,070,682	68,160,559
Rollover contributions	14,599,386	12,545,560
Total contributions	<u>134,234,390</u>	<u>143,314,218</u>
Proceeds from settlement (see Note 8)	<u>1,011,242</u>	<u>-</u>
Total additions	461,228,791	459,660,546
Deductions from net assets attributed to:		
Benefits paid to participants	258,708,525	252,119,837
Administrative expenses	644,417	490,132
Total deductions	<u>259,352,942</u>	<u>252,609,969</u>
Net increase in net assets available for benefits	201,875,849	207,050,577
Net assets available for benefits		
Beginning of year	2,171,904,593	1,964,854,016
End of year	<u><u>\$ 2,373,780,442</u></u>	<u><u>\$ 2,171,904,593</u></u>

The accompanying notes are an integral part of these financial statements.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

1. Description of Plan

The following description of the Teva Pharmaceuticals Retirement Savings Plan (the “Plan”) provides only general information. Participants should refer to the Summary Plan Description and the Plan document for a more complete description of the Plan’s provisions. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”).

General

The Plan is a defined contribution plan sponsored by Teva Pharmaceuticals USA, Inc. (“Teva” or the “Company”). Employees covered by a collective bargaining agreement, nonresident aliens, leased employees, employees rendering services in Puerto Rico who are receiving income that is taxable under the Puerto Rico Internal Revenue Code of 2011, as amended, and temporary or independent contractors are generally excluded from participating in the Plan. Employees are able to enroll in the Plan beginning the first day of each calendar month after their date of hire. Effective January 1, 2019, the Plan was amended and restated. Fidelity Management Trust Company is the trustee of the Plan.

Contributions

Participants may contribute 1% to 75% of compensation as a tax-deferred contribution or as a Roth contribution, as defined in the Plan. A participant may not elect to make both tax-deferred contributions and Roth contributions with respect to the same payroll period. In the event a participant fails to designate whether his or her elective contributions are to be characterized as tax-deferred or Roth contributions, such elective contributions will be characterized as tax-deferred. Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans.

The Plan provides for employer matching contributions which equal 100% of the first 6% of employee contributions.

As detailed in the Plan document, new employees are subject to automatic enrollment and will be deemed to have elected to make tax-deferred contributions to the Plan at a rate equal to 4% of their eligible compensation. Such tax-deferred contributions commence with respect to the first payday that occurs on the date with or following the 45th day following the date the employee is eligible to participate in the Plan. The participant will be provided a notice describing the terms and conditions of automatic enrollment and has until the end of the 45-day period to elect not to make automatic tax-deferred contributions, to modify the amount of such tax-deferred contributions, or to make Roth contributions. Such participant may withdraw their contributions, plus any income and minus any losses by notifying the Teva Pharmaceuticals USA, Inc. Compensation and Employee Benefits Committee (the “Committee”) during the 90-day period following the first contribution. In the absence of investment direction by the participant, any contributions made to the Plan and any related matching contributions will be invested in a qualified default investment alternative within the meaning of DOL Regulation Section 2550.404c-5.

The Plan provides for a Defined Contribution to the Plan. The Defined Contribution rate is 3.75% of eligible compensation plus 2% of eligible compensation in excess of the wage base for Plan years commencing on or after January 1, 2016. The Defined Contribution, as detailed in the Plan document, is allocated to each participant who is employed by Teva on the last work day of the last payroll period of the Plan year and has completed 1,000 hours of service during the Plan year. The Defined Contribution was \$25,822,433 and \$28,139,453 for the years ended December 31, 2021 and 2020, respectively. During 2022, the Company used forfeitures of \$3,877,607 to fund a portion of the 2021 Defined Contribution amount.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Participant Accounts

Each participant's account is credited with the participant's contribution, Teva's matching contribution, allocations of Teva's Defined Contribution and Plan earnings, and is charged with an allocation of administrative expenses. Allocations of the Defined Contribution are based on participant compensation, as defined in the Plan document. Allocations of Plan earnings and administrative expenses are based on participant account balances as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants are immediately vested in their contributions plus actual earnings thereon. Participants are 100 percent vested in Teva's Defined Contribution portion of their accounts plus actual earnings thereon after three years of credited service. With regards to Teva's matching contribution, participants who performed an hour or more of service prior to January 1, 2016, are immediately vested in the matching contribution. Participants who did not perform a minimum of an hour of service prior to January 1, 2016 become 100 percent vested in Teva's matching contribution portion of their accounts plus actual earnings thereon after three years of credited service.

Forfeited and Other Unallocated Accounts

Forfeited amounts, if any, may be used at the discretion of the Committee to restore accounts of reemployed participants, to fund matching contributions or the Defined Contribution or to pay Plan expenses (see Note 9). The unallocated forfeiture balance was \$4,947,647 and \$1,812,086 as of December 31, 2021 and 2020, respectively. During 2021 and 2020, approximately \$1,267,019 and \$2,437,507 of previously forfeited accounts were used to offset employer contributions, respectively.

Additionally, as of December 31, 2021 and 2020, the Plan had \$823 and \$2,509 of amounts in unallocated accounts which the Plan can use to pay for administrative expenses or allocate to participants. During the year ended December 31, 2021, \$1,704 was used to pay administrative expenses and no amounts were allocated to participants. During the year ended December 31, 2020, \$167,743 was used to pay administrative expenses and no amounts were allocated to participant accounts.

Investment Options

Participants direct the investment of their contributions into various mutual fund investment options and common collective trusts offered by the Plan and maintained by the trustee of the Plan. Participants direct the investment of their contributions into various fund investment options offered by the Plan in 1% increments. Investment performance is dependent on the investment experience, which is variable and not guaranteed. The Plan's exposure to credit loss in the event of nonperformance of investments managed by the trustee is limited to the carrying value of such investments.

Payment of Benefits

Distributions from the Plan are permitted under the following circumstances:

- Retirement or age 59-1/2;
- Death;
- Termination of employment;
- Hardship withdrawals.

A participant may elect to receive either a single lump sum payment or annual installments over a period not to exceed the joint life expectancy of the participant and the participant's designated beneficiary.

The beneficiary of a participant who is married on the date of the participant's death will be the surviving spouse. If the participant is not married or if the participant's surviving spouse consents to the designation of another beneficiary as detailed in the Plan document, the participant's designated beneficiary is entitled to the death benefits provided.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Notes Receivable from Participants

Plan participants may generally request loans for a minimum of \$1,000 up to a maximum generally equal to the lesser of \$50,000 or 50 percent of the participant's vested account balance. All loans are payable within five years, provided however, if the loan qualifies as a primary residence loan, the length of the loan shall not exceed ten years. Loans made under the provisions of a predecessor plan may remain outstanding until repaid in accordance with the terms of the predecessor plan. No more than two loans to a participant may be outstanding at any given time. The participant loans bear interest at rates which are commensurate with current interest rates charged by commercial lending institutions. Interest is charged to the account of the borrower. The loans are secured by the balance in the participant's account. Principal and interest are paid ratably through payroll deductions.

CARES Act Provisions Adopted

Effective March 27, 2020, the Plan adopted provisions under the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") including:

- Permitting qualified participants to receive coronavirus-related distributions. Eligible coronavirus-related distributions could be taken up to December 30, 2020 and may be repaid within three years; and
- Allowing for qualified participants to suspend loan repayments due through December 31, 2020. Suspended loan repayments resumed during 2021, and the loans were reamortized to extend the payoff period by one year and include accrued interest for the suspension period.

2. Summary of Significant Accounting Policies

The following are the significant accounting policies followed by the Plan:

Basis of Accounting

The financial statements of the Plan have been prepared on the accrual basis of accounting.

Investment Valuation and Income Recognition

Investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Plan's investment committee determines the Plan's valuation policies utilizing information provided by trustees, custodians and investment advisors. See Note 4 for discussion of fair value measurements.

Purchases and sales of investments are recorded on a trade-date basis. Interest income is accrued when earned. Dividend income is recorded on the ex-dividend date. Net appreciation in the fair value of investments includes the Plan's gains and losses on investments bought and sold as well as held during the year.

Notes Receivable from Participants

Notes receivable from participants (participant loans for Form 5500 reporting purposes) are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent participant loans are reclassified as distributions based upon the terms of the Plan document.

Contributions

Employer matching contributions are accrued based on eligible employee contributions which are generally recorded based on payroll withholdings.

Excess Contributions Payable

The Plan is required to return contributions received during the Plan year in excess of the Internal Revenue Code ("IRC") limits. At December 31, 2021 and 2020, the Plan had excess contributions. Such excess contributions are recorded as a liability with a corresponding reduction to contributions. The Plan distributed the 2021 and 2020 excess contributions to the applicable participants during 2022 and 2021, respectively.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires Plan management to make significant estimates and assumptions that affect the reported amounts of net assets available for benefits at the date of the financial statements and the changes in net assets available for benefits during the reporting period, and, when applicable, disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

Payment of Benefits

Benefits are recorded when paid.

Administrative Expenses

Certain expenses of maintaining the Plan are paid directly by Teva and are excluded from these financial statements. Fees related to the administration of notes receivable and other participant-specific fees are charged directly to the participant's account and are included in administrative expenses. Investment related expenses are included in net appreciation in fair value of investments. Certain other professional expenses of the Plan and its participants are partially offset through income generated from revenue sharing agreements (which is reported in the statements of changes in net assets available for benefits as other income, see Note 5).

Subsequent Events

The Plan has evaluated subsequent events through September 22, 2022, the date the financial statements were available to be issued.

3. Information Certified by a Qualified Institution

The Plan administrator having determined that it is permissible in the circumstances elected to have the audits of the Plan performed in accordance with ERISA section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Accordingly, as permitted under such election, the following information included in the accompanying financial statements and ERISA-required supplemental schedule of assets (held at end of year) was obtained or derived from information obtained by the Plan administrator and certified as complete and accurate by Fidelity Management Trust Company, trustee of the Plan and a qualified institution, in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA:

- Investments, at fair value, and notes receivable from participants, as shown in the statements of net assets available for benefits as of December 31, 2021 and 2020.
- Investment activity, including dividends, interest, net appreciation in fair value of investments, other income and interest income on notes receivable from participants, as shown in the statements of changes in net assets available for benefits for the years ended December 31, 2021 and 2020.
- The information for all registered investment companies (mutual funds), common collective trusts, and participant loans listed in the schedule of assets (held at end of year) as of December 31, 2021 as shown in the ERISA-required supplemental schedules.

4. Fair Value Measurements

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described as follows:

- Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
- Level 2: Inputs to the valuation methodology include:
 - Quoted prices for similar assets or liabilities in active markets;

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in methodologies used at December 31, 2021 and 2020.

Mutual funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the U.S. Securities and Exchange Commission. These funds are required to publish their daily net asset value ("NAV") and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Common collective trusts: Valued at the net asset value (NAV) or equivalent based on units of the common collective trust. The NAV, as provided by the custodian, is used as a practical expedient to estimate fair value. The NAV is generally based on the fair value of the underlying investments held by the common collective trust less its liabilities. This practical expedient is not used when it is determined to be probable that the common collective trust will sell the investment for an amount different than the reported NAV.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table sets forth by level, within the fair value hierarchy, the Plan's fair value measurements as of December 31, 2021:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments, at fair value:				
Mutual funds	\$ 281,153,531	\$ 281,153,531	\$ -	\$ -
Common collective trusts (*)	2,048,963,162	-	-	-
Total	<u>\$ 2,330,116,693</u>	<u>\$ 281,153,531</u>	<u>\$ -</u>	<u>\$ -</u>

The following table sets forth by level, within the fair value hierarchy, the Plan's fair value measurements as of December 31, 2020:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Investments, at fair value:				
Mutual funds	\$ 249,235,823	\$ 249,235,823	\$ -	\$ -
Common collective trusts (*)	1,869,938,589	-	-	-
Total	<u>\$ 2,119,174,412</u>	<u>\$ 249,235,823</u>	<u>\$ -</u>	<u>\$ -</u>

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

*In accordance with fair value measurement guidance, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented as investments in the statements of net assets available for benefits.

The following table sets forth additional disclosures for the fair value measurement of investments in certain entities that calculate net asset value per share (or its equivalent) as of December 31, 2021 and 2020.

<u>Investment Type</u>	<u>Fair Value</u>	<u>Fair Value</u>	<u>Unfunded</u>	<u>Redemption</u>	<u>Redemption</u>
	<u>December 31,</u>	<u>December 31,</u>			
	<u>2021</u>	<u>2020</u>	<u>Commitments</u>	<u>Frequency</u>	<u>Notice Period</u>
Common collective trusts	\$ 2,048,963,162	\$ 1,869,938,589	\$ -	Daily	Daily

The Plan is applying the practical expedient as of December 31, 2021 and 2020 to its common collective trusts.

The Plan's investment options include common collective trusts whose investment strategies are similar to target date funds, equity style funds and fixed income style funds. The objective of common collective trusts with target date strategies is to provide an age-based investment mix of stocks, bonds and short-term investments. The objectives of the common collective trusts invested in equity investments is to approximate the risk and return characterized by various indices; to seek long term capital appreciation; provide diversified exposure representative of various segments of the U.S. or foreign equity market; and/or to seek income. The objective of the common collective trusts invested in fixed income is to provide investment results that approximate the overall performance of certain bond indices and/or to provide a predictable rate of return while preserving the safety of capital and minimizing market risk. These common collective trusts are redeemable at net asset value under agreements with the underlying common collective trusts. However, it is possible that these redemption rights may be restricted by the common collective trusts in the future in accordance with underlying common collective trust agreements. Due to the nature of the investments held by the common collective trusts, changes in market conditions and the economic environment may significantly impact the net asset value of the common collective trusts, and consequently, the fair value of the Plan's interest in the common collective trusts. Furthermore, changes in the liquidity provisions of the common collective trusts may significantly impact the fair value of the Plan's interest in the common collective trusts.

The T. Rowe Price Stable Value Fund's (the "Stable Value Fund") investment objective is to maximize current income consistent with maintenance of principal and to provide for withdrawals for certain participant-initiated transactions under a retirement plan without penalty or adjustment. The Stable Value Fund invests principally in guaranteed investment contracts issued by insurance companies, investment contracts issued by banks, synthetic investment contracts issued by banks, insurance companies and other issuers, as well as other similar instruments. Participants' ownership of the Stable Value Fund is represented as units. Units are issued and redeemed daily at the Stable Value Fund's constant NAV of \$1 per unit. The Stable Value Fund allows for daily liquidity, with no additional days' notice required for redemption. It is the policy of the Stable Value Fund to use its best efforts to maintain a stable NAV of \$1 per unit, although there is no guarantee that the Stable Value Fund will be able to maintain this value.

The Stable Value Fund invests in assets (typically fixed income securities or bond funds, and may include derivative instruments such as futures contracts and swap agreements) and enters into "wrap" contracts issued by third parties and invests in cash equivalents represented by shares in a money market fund. Wrap contracts are designed to allow a stable value portfolio to maintain a constant NAV and protect a portfolio in extreme circumstances. In a typical wrap contract, the wrap issuer agrees to pay a portfolio the difference between the contract value and the market value of the underlying assets once the market value has been totally exhausted.

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

The Stable Value Fund is unlikely to maintain a stable NAV if, for any reason, it cannot obtain or maintain wrap contracts covering all of its underlying assets that are not otherwise invested in money market funds.

5. Related-Party and Party in Interest Transactions

Plan investments include various investment options managed by affiliates of Fidelity Management Trust Company ("FMTC"). FMTC provides recordkeeping, trustee and custodial services to the Plan. Since FMTC is the trustee as defined by the Plan, administrative fees charged by FMTC that are paid from Plan assets qualify as party-in-interest transactions. These transactions are not, however, considered prohibited transactions under 29 CFR 408(b) of the ERISA regulations. Additionally, for participants who have elected to take a participant loan, the loans are secured by the respective participant's account balance. Fees paid by the Plan for the administrative services were \$644,417 and \$490,132 for the years ended December 31, 2021 and 2020, respectively. The Plan is interpreted, administered and operated by an Administrative Committee comprised entirely of executives of the Company.

FMTC or its affiliates generate income to the Plan through revenue sharing agreements. More specifically, FMTC or its affiliates may receive revenue from mutual fund and common collective trust service providers for services FMTC or its affiliates provide to the mutual funds and common collective trust. This revenue may be used to offset certain amounts owed to FMTC or its affiliates for administrative services to the Plan. If the revenue received by FMTC or its affiliates from such mutual fund or common collective trust service providers exceeds the amount owed as agreed to by FMTC and the Plan for administrative services, FMTC or its affiliates is to remit the excess to the Plan. Such amounts may be applied to pay Plan administrative expenses or allocated to the accounts of the participants. During the years ended December 31, 2021 and 2020, the related amounts deposited into the Plan and allocated directly to participant accounts were \$93,958 and \$38,896, respectively. The Plan or Plan Sponsor may make a payment to FMTC or its affiliates for administrative expenses not covered by revenue sharing.

During 2021, the Company failed to remit to the Plan's trustee certain employee contributions totaling \$4,024 within the period prescribed by the Department of Labor regulations. During 2022, the Company made contributions to the affected participants' accounts to compensate those participants for potential lost income due to the processing delays. The Company believes that these transactions do not affect the tax status of the Plan and took action prescribed by the regulations to remedy such errors.

6. Plan Termination

Although Teva has not expressed any intent to discontinue the Plan, Teva may do so at any time with consent of the trustee and subject to the provisions of ERISA. In the event of such discontinuance resulting in the termination of the Plan, participants would become 100 percent vested in their employer contributions and the net assets of the Plan would be distributed to Plan participants and beneficiaries in proportion to their respective account balances.

7. Tax Status

The Internal Revenue Service has determined and informed the Company by letter dated June 7, 2016, that the Plan was designed as a qualified trust in accordance with the applicable sections of the Internal Revenue Code (the "IRC"). The Plan has been amended since receiving the determination letter. However, the Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the IRC. Therefore, the Plan administrator believes the Plan, as amended, is qualified and the related trust is tax-exempt, and therefore, no provision for income taxes has been included in the Plan's financial statements.

Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. The plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021,

Teva Pharmaceuticals Retirement Savings Plan
Notes to Financial Statements
As of and for the Years Ended December 31, 2021 and 2020

there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan administrator believes it is no longer subject to income tax examinations for years prior to 2018.

8. Risks and Uncertainties

The Plan invests in various investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits and the statements of changes in net assets available for benefits.

On December 5, 2019, a lawsuit was filed against the Company, its Board of Directors (the "Board") and Investment Committee (the "Committee"), and other defendants (collectively the "Defendants") regarding the investment options and fees associated with the Plan, under 29 U.S.C. sections 1109 and 1132(a)(2), Pinnell, et. al. v. Teva Pharmaceuticals USA, Inc. et. al., Case No. 19-5738 (E.D. Pennsylvania). The Plan itself is not named as a defendant. The complaint alleges that the Defendants breached the fiduciary duties of prudence and loyalty imposed by the federal Employee Retirement Income Security Act ("ERISA") by (1) selecting for the Plan certain investment options that allegedly charged "excessive" investment management fees when lower-cost/better-performing investments were available; and (2) allowing the Plans participants to pay excessive recordkeeping fees. On March 3, 2020, Defendants filed a motion to dismiss the Amended Complaint, seeking the dismissal with prejudice of all claims. The motion to dismiss was denied and the parties engaged in discovery on the limited issues of plaintiffs' individual claims and class certification. On June 11, 2021, the United States District Court for the Eastern District of Pennsylvania accepted and approved the parties' negotiated final settlement of all claims for \$2,550,000 without any admission of wrongdoing and thus closing out the litigation. In December 2021, \$1,011,242 was contributed to the Plan in accordance with the settlement agreement and is recorded as settlement proceeds on the statement of changes in net assets available for benefits for the year ended December 31, 2021. The settlement funds were allocated to the accounts of impacted participants in accordance with the amounts calculated by the settlement administrator. In accordance with the settlement agreement, class members without Plan accounts were paid directly by the settlement administrator a total of \$523,302. The remaining amount were allocated for class counsel fees and other fees.

9. Plan Amendments

During 2021, the Plan was amended in order to:

- Allow the Plan to use forfeitures to pay Plan expenses effective June 1, 2021;
- Incorporate provisions of the Setting Every Community Up for Retirement Enhancement Act (the "SECURE Act") and CARES Act;
- Change the requirement, effective January 1, 2022, from being employed on the last work day of the last payroll period of the Plan year to being employed by the employer on the last day of the Plan year in order to receive the Defined Contribution;
- Make other general administrative changes.

SUPPLEMENTAL SCHEDULES

Teva Pharmaceuticals Retirement Savings Plan
Schedule H, Line 4(i) – Schedule of Assets (Held at End of Year)
As of December 31, 2021

EIN: 22-1734359 Plan #004

(a)	(b) Identity of issue, borrower, lessor or similar party	(c) Description of investment including maturity date, rate of interest, collateral, par or maturity value	(e) Current value
	Registered Investment Companies (Mutual Funds):		
	Vanguard	Inflation Protected Bond Fund	\$ 21,427,531
	BlackRock	Total Return Fund	920,334
	Cohen & Steers	Real Estate Fund	30,267,946
*	Fidelity	Diversified International Fund	35,628,516
	T. Rowe Price	Large Capital Value Fund	63,500,911
	T. Rowe Price	U.S. Treasury Money Fund	4,948,470
	Vanguard	Wellington Fund	58,010,563
	Boston Trust	SMID Cap Fund	1,653,777
	Prudential	Jennison Small Company Fund	64,795,483
	Common Collective Trusts:		
	State Street	Retirement Income Fund	25,072,346
	State Street	Retirement 2020 Fund	69,125,227
	State Street	Retirement 2025 Fund	136,817,873
	State Street	Retirement 2030 Fund	220,138,259
	State Street	Retirement 2035 Fund	222,285,108
	State Street	Retirement 2040 Fund	199,044,196
	State Street	Retirement 2045 Fund	141,267,757
	State Street	Retirement 2050 Fund	59,421,758
	State Street	Retirement 2055 Fund	26,504,251
	State Street	Retirement 2060 Fund	7,719,265
	State Street	Retirement 2065 Fund	1,212,567
	State Street	Global All Cap Equity Fund	42,651,872
	State Street	Small/Mid Cap Index Fund	131,230,640
	State Street	S&P 500 Index Fund	282,096,740
	State Street	U.S. Bond Index Fund	50,438,497
	T. Rowe Price	Stable Value Fund	145,181,108
	T. Rowe Price	Large Cap Growth Fund	288,755,698
*	Participant Loans	Interest rates of 4.25% - 6.50% with maturities through 2041	19,528,596
			<u>\$ 2,349,645,289</u>

*: Party-in-interest

"Cost" is not required as all the investments are participant-directed. The cost value of participant loans is \$0.

The information in this schedule has been derived from information certified as to its completeness and accuracy by Fidelity Management Trust Company, a qualified institution.

Teva Pharmaceuticals Retirement Savings Plan
Schedule H, Line 4(a) – Schedule of Delinquent Participant Contributions
For the Year Ended December 31, 2021

	EIN 22-1734359 Plan #004			
Participant Contributions Transferred Late to Plan	Total that Constitute Nonexempt Prohibited Transactions			Total Fully Corrected Under VFCP and PTE 2002-51
Check Here if Late Participant Loan Repayments are included:[]	Contributions Not Corrected	Contributions Corrected Outside VFCP	Contributions Pending Correction in VFCP	
2021* \$4,024	\$4,024	-	-	-

- * During 2021, the Company failed to remit to the Plan's trustee certain employee contributions totaling \$4,024 within the period prescribed by the Department of Labor regulations. During 2022, the Company made contributions to the affected participants' accounts to compensate those participants for potential lost income due to the processing delays. The Company believes that these transactions do not affect the tax status of the Plan and took action prescribed by the regulations to remedy such errors.